ENVIRONMENTAL,
SOCIAL AND GOVERNANCE
(ESG) REPORT
Shenzhen Kangtai Biological Products Co., Ltd.
Company Website: www.biokangtai.com
Tel: 0755-26988558
E-mail: office@biokangtai.com
Address: Kangtai Group Building, No. 222 Kefa Road, Science Park Community, Yuehai Subdistrict, Nanshan District, Shenzhen
Table of About BioKangtai 01
Governance with Integri-
ty for Steady and Sus-
tainable Corporate Devel-
ous Value Ecosystem
Contents
opment
Sustainable Development Governance 04
ESG Management 04
Standardized Governance 11 Employee Rights and Interests 30
Stakeholder Communication 05
Compliance and Risk Management 13 Training and Development 33
Material Topic Identi?cation 06
Business Ethics 14 Occupational Health and Safety 33
Due Diligence 09
Information Security Protection 15 Rural Revitalization and Social Public Welfare 36
Pharmacovigilance 16 Health and Medical Accessibility 36
Ef?cient Operations for Excellence in Innovation
Green and Sustainable for Shaping the Future of
Development the Industry
Appendices Climate Change Response 18 R&D and Innovation 38
About this Report 48 Environmental Compliance Management 21 Product Quality and Safety 41
ESG Performance Table 49 Pollutant Emission and Waste Disposal 23 Customer Relationship Management 44
ESG Indicator Index 51 Resource Utilization and Circular Economy 25 Supply Chain Management 45
Biodiversity Conservation Collaboration with Industry Peers
CONTENTS
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 01
About BioKangtai
Founded in 1992, Shenzhen Kangtai Biological Products Co., Ltd. (Stock Code: 300601) is dedicated to the research and development, production and sales of human vaccines. It has
now developed into an innovative biopharmaceutical enterprise with strong R&D capabilities, a rich product portfolio, a leading industrial scale and remarkable international develop-
ment in China.
The Company has established 5 major R&D and industrial bases in Shenzhen and Beijing, and built diversified R&D platforms covering live attenuated viral vaccines, inactivated viral
vaccines, genetic engineering protein vaccines, bacterial polysaccharide vaccines, bacterial polysaccharide conjugate vaccines, combined vaccines, viral vector vaccines, mRNA
vaccines and new adjuvant technologies, laying a solid foundation for the transformation of cutting-edge vaccine technology achievements into practical applications.
Relying on its strong technological reserves and achievement transformation capabilities, the Company has 14 products approved for market launch or emergency use, including core
varieties such as the world’s first 60 μg hepatitis B vaccine, the “Dual-Carrier 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine”, and China’s first approved “Four-Dose
Regimen” Human Diploid Cell Rabies Vaccine. Its marketing and distribution network covers 31 provinces, autonomous regions and municipalities directly under the Central Govern-
ment of China. In addition, the Company has continuously improved its “short?term + medium?term + long?term” stepped R&D pipeline, with nearly 30 pipeline candidates under
development, including pentavalent vaccines, hexavalent vaccines, quadrivalent inactivated enterovirus vaccines (Vero cells), 24?valent pneumococcal vaccines, Klebsiella pneumoni-
ae vaccines, and recombinant hepatitis B vaccines (Saccharomyces cerevisiae, 60μg) for preventing HBsAg reversion in patients with chronic hepatitis B who have achieved clinical
cure, Respiratory Syncytial Virus(RSV) vaccine,RSV-human metapneumovirus(hMPV) combined vaccine and so on, basically covering all key vaccine categories worldwide.
The Company has deeply pursued an internationalization strategy and successively signed cooperation agreements with partners from more than 20 countries, forming an interna-
tional cooperation network covering Southeast Asia, South Asia, the Middle East, Central Asia, Africa, Eastern Europe, Latin America and other regions, promoting an upgrade from
“product export” to “technology export”. By building a diversified international cooperation network and overseas marketing system, the Company has continuously expanded into
emerging markets, enhanced global vaccine supply capacity, supported the development of public health systems in developing countries, and helped narrow the global health gap.
In the future, the Company will be driven by the dual engines of innovative R&D and globalization, strengthen breakthroughs in cutting-edge technologies and iterative pipeline
reserves, keep abreast of cutting-edge trends and industrial transformation opportunities in the biomedical sector, and deploy high-quality tracks aligned with its development
strategy and industrial layout to consolidate its core competitive advantages. Meanwhile, it will accelerate its global strategic layout, expand overseas markets, enhance international
competitiveness, strive to become a world-renowned multinational biopharmaceutical enterprise, and contribute greater strength to the global public health cause.
Corporate Culture
Corporate Tenet Core Values Corporate Vision
Create better vaccines, benefit human Integrity, Efficiency, Innovation,Synergy, To become a century-old multinational biopharmaceuti-
health. Excellence. cal group leading domestically and internationally
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 02
Development History
BioKangtai Park in Guang- The 23-Valent Pneumo- The COVID-19 Inactivated Vaccine was The production base of the Recombi- TThe Freeze-dried Human The Live Attenuated Varicella Vaccine Sabin strain inactivated poliomy- Quadrivalent influenza virus split
ming District, Shenzhen coccal Polysaccharide approved for emergency use in China. nant COVID-19 Vaccine (Y25 Adenovi- Rabies Vaccine (Human obtained the drug registration certificate. elitis vaccine (Vero cells) has vaccine and adsorbed tetanus
was officially put into use. Vaccine obtained the rus Vector) obtained a Certificate of Diploid Cell) obtained the obtained the Drug Registration vaccine has obtained the Drug
The Recombinant COVID-19 Vaccine The International Industrial Base for New
GMP certificate and was Compliance issued by a Qualified drug registration certificate. Certificate. Registration Certificate.
(Y25 Adenovirus Vector) obtained Vaccines Project of Beijing Minhai
launched on the market. Person (QP) of the European Union.
Emergency Use Authorization (EUA) Biotechnology Co., Ltd. was officially put
from the Badan Pengawas Obat dan The vaccine production base in into use.
Makanan (BPOM). Guangming District, Shenzhen
Kangtai Innovation Plaza, the Group's
obtained a GMP Certificate of Compli-
The 13-Valent Pneumococcal Polysac- headquarters building, was put into use
ance issued by the Food and Drug
charide Conjugate Vaccine obtained the and positioned as an important R&D and
Administration of the Philippines.
drug registration certificate. headquarters agglomeration center for
the biotech industry in Shenzhen.
The Company was listed on Beijing Minhai Biotechnolo- The hepatitis B vaccine obtained GMP certification in The Measles and Rubella Combined The Haemophilus Influenzae Type b The 20 μg/1.0ml/dose hepatitis B The first 60 μg/1.0ml/dose hepatitis B
the ChiNext Board of the gy Co., Ltd. established the accordance with the 2010 Edition Standards. Live Attenuated Vaccine obtained Conjugate Vaccine obtained GMP vaccine for adult use was successfully vaccine for non-responder adults in
Shenzhen Stock Exchange. National and Local Joint GMP certification. certification. developed. China was successfully developed.
The Haemophilus Influenzae Type b Conjugate Vaccine
Engineering Laboratory for
(prefilled syringe)obtained GMP certification. The Postdoctoral Research Worksta- The Diphtheria, Tetanus, Acellular The 10 μg/0.5ml/dose hepatitis B The hepatitis B vaccine obtained GMP
New Vaccine Development
tion was established at Beijing Minhai Pertussis and Haemophilus Influenzae vaccine for pediatric use was success- certification for the third time.
Technologies. The Company introduced Inactivated Poliomyelitis Vaccine
Biotechnology Co., Ltd. Type b Combined Vaccine obtained fully developed.
technology in cooperation with Intravacc of the Nether-
lands and the World Health Organization (WHO). GMP certification.
Beijing Minhai Biotechnology Co., Ltd. established the
Beijing Engineering Technology Research Center for New
Combined Vaccines, the Academician Expert Workstation
and the Beijing International Science and Technology
Cooperation Base for New Vaccines.
BioKangtai was The 5 μg hepatitis B vaccine was The 5 μg/0.5ml/dose hepatitis B vaccine The hepatitis B vaccine The 10 μg/1.0ml/dose hepatitis The first hepatitis B The 10 μg/0.5ml/dose hepatitis B vaccine for adult use was After strategic reorganization,
founded. successfully trial-produced and met the quality standards of Merck & Co., obtained GMP certifica- B vaccine for adult use was vaccine with a three-year newly launched to replace the 10 μg/1.0ml/dose specification. Beijing Minhai Biotechnology Co.,
passed the acceptance inspection Inc. of the United States and obtained the tion for the first time. successfully developed. validity period in China Ltd. became a wholly-owned
The hepatitis B vaccine obtained GMP certification for the
by the Ministry of Health. trial production approval certificate from was successfully subsidiary of BioKangtai.
second time.
the Ministry of Health. developed.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 03
Corporate Honors 2025
BioKangtai
The Second Batch of Shenzhen
Shenzhen Guangcai Program 2025 Top 100 Industry Leader
Manufacturing Single Champion Caring Enterprise
Contribution Award Enterprises in Shenzhen
Enterprises (2025–2028)
Industry and Information Technology Bureau of CPC Shenzhen Municipal Committee, Shenzhen Shenzhen Industry Leader Corporate Development Federation of Industry and Commerce (Chamber of Com-
Shenzhen Municipality Municipal People’s Government and Promotion Association, Shenzhen Economic Daily merce), Matian Subdistrict, Guangming District, Shenzhen
Caring Enterprise “Excellent Council Member” of
Outstanding Contribution Award 2025 Shenzhen Green Factory Shenzhen Biomedical Indus-
try-Education Alliance
Federation of Industry and Commerce (Chamber of Com- Industry and Information Technology Bureau of Shenzhen Biomedical Industry-Education
merce), Matian Subdistrict, Guangming District, Shenzhen Shenzhen Municipality Alliance
BioMinhai
Second Prize of Beijing Science Beijing Key Laboratory of
Beijing Intellectual Property Second Prize of Jiangsu Science
and Technology Progress Award Synthetic Immunology and
Advantage Unit and Technology Progress Award
Vaccine Manufacturing
Beijing Municipal Science and Beijing Municipal Intellectual People's Government of Jiangsu
People's Government of Beijing Municipality
Technology Commission Property Office Province
Beijing Low-Carbon Leader
in Beijing for Scientific and Responsibility of Private Enter- National Green Factory
Excellent Unit
Technological Innovation prises in Beijing
Beijing Municipal Bureau of Ecology Federation of Industry and Commerce Federation of Industry and Commerce Ministry of Industry and Information Technology
and Environment of Daxing District of Daxing District of the People's Republic of China
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 04
Sustainable Development Governance
Key Performance
ESG Man- Guided by the concept of sustainable development, the Company regards ESG management as a critical element of corporate development and
actively engages in the development of the ESG system with a long-term strategic vision. To further strengthen ESG governance, the Company
agement
During the reporting period, the Company
has incorporated ESG responsibilities into the functions of the Strategy Committee and defined its ESG management duties and authority in the
Detailed Rules for the Work of the Strategy Committee of the Board of Directors.
ESG training sessions and seminars
Level Composition Responsibilities
Decide on and approve the Company’s ESG strategy to ensure alignment with the Company’s long-term
development strategy;
Review and approve the Company’s ESG policies, objectives and key performance indicators, and supervise
Board of Directors/Strate-
their implementation;
gy Committee of the
Decision-Making Level Board of Directors Oversee the identification, assessment and management of material ESG risks and opportunities of the
Company;
Review and approve the Company’s annual sustainable development report and other material ESG disclo-
sures.
Review the Company’s ESG strategy, objectives, policies and material topics, and report to the Board of
Directors and its special committees;
Examine the assessment results of material ESG risks and opportunities, and coordinate various depart-
ments to formulate countermeasures;
ESG Working Group
Management Level Review the Company’s annual sustainable development report to ensure its completeness and accuracy;
Promote the consistent implementation of the ESG strategy at all levels of the Company, and coordinate
ESG-related work among various departments.
Implement the Company’s ESG strategic plans in light of respective businesses, improve ESG policies of
various departments, and advance the achievement of ESG objectives;
Risk and Opportunity Identification
Conduct ESG risk identification, assessment and control for respective businesses, and report material risks
in a timely manner; The Company assesses environment-, social- and governance-related risks and
Relevant Departments opportunities in accordance with the COSO Enterprise Risk Management Frame-
Regularly collect and analyze ESG-related data, and report on the completion of ESG performance;
Implementation Level
work, conducts identification, supervision and management of ESG gover-
Cooperate in the completion of ESG information disclosure, project implementation, stakeholder engage-
ment and other tasks; identify and promote ESG best practices, participate in training, and facilitate experi- nance-related topics and activities, and promotes the effective implementation
ence sharing and continuous improvement among various departments. of the sustainable development strategy. In 2025, the Company did not experi-
ence any material risk incidents in the ESG domain.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 05
Stakeholder Communication
The Company understands and responds to the expectations and demands of various stakeholders through standardized and systematic stakeholder communication procedures, so as to enhance the Company’s operation and management capabilities and sustainable development
capacity.
Stakeholders Shareholders and Investors Government and Regulatory Authorities Management Level Employees Customers Partners Community Partners
Investors Governments and competent Members of the Board of Ordinary employees Domestic and Suppliers Surrounding communities
authorities at all levels Directors overseas customers
Contractors Universities and research
Potential investors
Shenzhen Stock Exchange Senior Management institutions
Partners
Stakeholder China Securities Regulatory Department Heads ESG rating agencies
Representatives Commission Media
Industry associations, etc.
Corporate business and funda-
mentals Law-abiding and compliant Strategic implementation Competitive salary and welfare Product quality and delivery Technical strength and Contribution to sustainable
operations and market competitive- benefits capability cooperation stability community development
Strategic development direction ness of the Company
Response to climate change Comprehensive training system Information security and Fair, impartial, open and Sharing of corporate develop-
of the Company
and carbon neutrality Efficient corporate privacy protection transparent procurement ment achievements
Stakeholder Open and transparent career
Financial performance and market management structure environment
Concerns Contributions to local development paths Green and low-carbon Reduction of environmental
prospects of the Company economic and industrial Profitability of the products Technical empowerment and impact
Workplace health and safety
development Company industrial development
Corporate governance and risk
management capabilities Market and sales support
Information disclosure Information disclosure Regular work reports Labor unions Pre-sales communication Supplier training Face-to-face communication
Shareholders’ meetings Participation in relevant Management meetings Email addresses After-sales service On-site audits and communi- Public welfare activities
meetings cation
Specialized training Enterprise collaborative
Investor research, roadshows and Routine communication (e.g., Hotlines for complaints
Communication Communication through office platform
strategy conferences Email addresses customer visits) Project cooperation
and Engagement industry associations and Media briefings
Methods other institutions Enterprise collaborative
Hotline and email Third-party training Regular visits
office platform Regular communication and
Supervisory Check for
Hudongyi Platform Customer audits feedback
Compliance
Performance briefings and other Project cooperation
communication activities
Official websites, official
WeChat accounts and other
public channels
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 06
Material Topic Based on the topics covered in the Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange No.17 – Sustainable Development Reports (for Trial Implementation) (hereinafter referred to as the “Guidelines”), the
Company conducts an in-depth analysis of its business structure and operation model, carries out research and analysis on stakeholders through surveys, and systematically identifies material topics that are intrinsically closely linked to
Identification the Company’s business activities and occupy a prominent position in the stakeholder concern matrix.
Aspect Definition Materiality Analysis Dimension
Whether the Company’s performance on the relevant topic may have actual or poten- • Likelihood of occurrence of the impact
Impact Materiality
tial material impacts on the economy, society and the environment. • Scale, scope and irreparability of the impact
Whether the topic is expected to exert material impacts on the Company’s business
• Likelihood of occurrence of the impact
Financial Materiality model, business operations, development strategies, financial position, operating
results, cash flows, financing methods and costs in the short, medium and long term. • Extent of financial impact
BioKangtai Dual Materiality Analysis Process for Topics
Step 1 Step 2 Step 3 Step 4
Background Identification Topic Materiality Assessment
Establishment of Topic List Topic Reporting
and Understanding and Confirmation
•Analyze macroeconomic •Conduct preliminary identifica- •Conduct material topic •The Company synthesizes the
policies and regulatory tion, screening and definition of assessment and confirmation questionnaire analysis results of
requirements to fully relevant sustainable development through research, interviews topic materiality and expert scoring
understand the Company’s topics by combining standard and other methods, and by opinions to form a dual materiality
sustainable development benchmarking, peer benchmarking referring to internal and topic matrix. Upon review and
background; and policy analysis; external expert opinions. confirmation by the Company’s
management, the dual materiality
•Identify key stakeholders •Analyze the actual and potential
topics for 2025 will serve as key
affected. impacts, risks and opportunities
disclosure items in this report.
involved in material topics.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 07
Topic List ESG Topic Library of BioKangtai 2025
In the process of identifying material topics for 2025, BioKangtai has fully considered the following five factors, identified and selected
ESG Topic Library of BioKangtai 2025
Climate Change Response, Pollutant Emission and Waste Disposal, Ecosystem and Biodiversity Conservation,
Environmental Environmental Compliance Management, Energy Utilization, Water Resource Utilization, Circular Economy, Clean-
Dimension Analysis Logic
er Production, Biosafety
R&D and Innovation, Tech Ethics, Product and Service Safety and Quality, Supply Chain Security, Equal Treatment
Focusing on the international strategy of steady progress featuring the parallel develop- Social for SMEs, Employees (Protection of Employee Rights and Interests, Employee Training and Development, Occupa-
ment of “bringing in” and “going global”, the Company sorts out ESG topics highly tional Health and Safety), Rural Revitalization, Social Contribution, Health and Medical Accessibility
Corporate Development Strategy relevant to its core competitiveness and future development direction.
Due Diligence, Stakeholder Communication, Anti-Commercial Bribery and Anti-Corruption, Anti-Unfair Competi-
Corporate
tion, Compliant Operation and Risk Management, Data Security and Customer Privacy Protection, Pharmacovigi-
Governance
lance
In accordance with national and local laws, regulations and policy documents, the
Company extracts ESG topics binding or guiding various business segments to ensure
Macroeconomic Policies that topic setting complies with policy orientations. Impact Materiality Assessment
In accordance with the Guidelines, the Company assesses the impact materiality of sustainable development-related topics from the two
dimensions of likelihood and severity of impacts. Among them, the likelihood of impact is assessed from the three dimensions of impact
By identifying major stakeholder groups and combining their key concerns and commu-
scale, scope and irreparability.
nication methods, the Company defines ESG topics requiring key responses to enhance
Stakeholder Identification
the responsiveness and relevance of topics. The Company has identified the key concerns of different stakeholders, ranked the impact materiality of the 25 topics on BioKangtai in
and Response
combination with expert judgments, and derived a list of impact material topics in accordance with the set impact materiality threshold.
Topics with Impact Materiality
With reference to mainstream ESG rating and disclosure standards including MSCI, SASB
and the Shenzhen Stock Exchange, the Company ensures that topic selection features
Rating and Information
international vision and industry applicability.
Disclosure Guidelines 1 Climate Change Response 1 R&D and Innovation 1 Pharmacovigilance
and Quality Anti-Corruption
By benchmarking the disclosure priorities of peers on ESG topics, the Company ensures 3 Supply Chain Security 3 Compliant Operation and Risk
that topic setting is industry-comparable and forward-looking. Management
Peer Benchmarking Analysis
Management
Privacy Protection
Disposal 5 Stakeholder Communication
Conservation
Environmental, Social and Governance (ESG) Report 2025 Part One
前篇 Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 08
Financial Materiality Assessment
The Company assesses the financial materiality of sustainable development-related Topics with Financial Materiality
topics across three time horizons: short term (within 1 to 2 years inclusive), medium term
(3 to 5 years inclusive) and long term (more than 5 years), from the two aspects of
likelihood of occurrence and extent of financial impact.
In the specific analysis process, the Company has set judgment values for the extent of
financial impact based on historical pre-tax profits, analyzed the likelihood of occurrence
of risks and opportunities of each topic in the short, medium and long terms and their 3 Supply Chain Security
impact on financial expectations, ranked the financial materiality of the 25 topics with
reference to expert opinions, and derived a list of financial material topics in accordance
with the set financial materiality threshold.
E
Topic Materiality Assessment Results
Environmental Compliance Management, Pollutant Emission and
The Company has comprehensively summarized the impacts, risks and opportunities of Materiality of impact on the economy, society, and environment
Waste Disposal, Biosafety, Water Resource Utilization, Circular
material topics, and disclosed relevant management actions and effectiveness in this
Economy, Cleaner Production
report. For topics with financial materiality, the Company conducts focused disclosure in
accordance with the four-element framework of “Governance”, “Strategy”, “Impacts, R&D and Innovation Product and Service
S
Risks and Opportunities Management” and “Indicators and Targets”. Safety and Quality
Employees, Health and Medical Accessibility, Equal Treatment for
SMEs, Tech Ethics
G
Anti-Commercial Bribery and Anti-Corruption, Compliant Opera-
Supply Chain Security Pharmacovigilance Energy Utilization
tion and Risk Management, Data Security and Privacy Protection,
Stakeholder Communication, Due Diligence
Ecosystem and Biodiversity Conservation, Rural Revitalization,
Climate Change Response
Social Public Welfare, Anti-Unfair Competition
Financial materiality to the company
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 09
Due Diligence
Topic Impact Scope Impacts Risks Opportunities Impact Cycle Management Strategies
Upstream Operations Downstream Short-term Medium-term Long-term
Large investment in R&D pipeline with uncertain Incremental revenue brought by the launch of multiva- Dynamically adjust R&D strategies according to key
Cost increase / commercialization, technological platforms lagging lent combination vaccines milestones, continuously invest in cutting-edge
R&D and Innovation
Revenue behind competitors, and pressure on long-term and blockbuster new products; platform technologies technology platforms and promote international
growth competitiveness. certification.
such as mRNA lay the foundation for future growth.
Implement comprehensive quality management,
Product and Cost increase / Unqualified batch release, challenges to quality Intelligent manufacturing and full-process traceability
realize full life cycle traceability based on digitaliza-
Service Safety and Revenue consistency brought by scale expansion, and enhance regulatory trust; application of new technolo-
tion, and continuously optimize by benchmarking
Quality reduction decrease of public trust caused by industrial crises. gies drives quality iteration.
international standards.
Risk of supply disruption due to import dependence
Domestic substitution reduces costs; IoT monitoring Implement multi-source supply and safety stock
Cost increase / on key materials, impact of extreme weather on
Supply Chain strategies, promote domestic substitution, and build a
Revenue and intelligent early warning improve resilience; green
Security cold-chain logistics, and increasingly stringent ESG
reduction supply chain facilitates global market access. digital emergency and green logistics system.
compliance requirements.
Regulatory penalties and public opinion crises
Active monitoring accumulates real-world data to Build a multi-channel monitoring system, implement
Cost increase / caused by improper handling of adverse reactions;
Pharmacovigilance support product improvement; efficient emergency dual risk assessment, and improve the compensation
Revenue amplified impact of incidents due to public sensitiv-
reduction mechanism enhances public trust. mechanism based on commercial insurance.
ity.
Rising energy prices push up costs, supply shortag- Energy-saving technological transformation reduces Establish an energy management system, improve
Cost increase /
Energy Utilization es cause production interruptions, and carbon unit energy consumption; application of renewable metering and optimize processes, and promote
Cost saving
trading increases compliance burdens. energy cuts long-term electricity costs. renewable energy substitution.
Strengthen climate change risk assessment and
Extreme weather impacts facilities and logistics,
Cost increase / Low-carbon vaccines meet emerging demands; response capacity development, formulate emergen-
Climate Change carbon policies increase compliance costs, and
Revenue climate-resilient supply chain enhances robustness; cy rescue plans for extreme weather, establish an
Response climate-related information disclosure require-
reduction improved ESG rating boosts financing attractiveness. emergency response mechanism and optimize
ments become stricter.
cold-chain logistics.
Analysis Table of Impacts, Risks and Opportunities of Financially Material Topics of BioKangtai in 2025
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 10
Governance
with Integrity
for Steady and
Sustainable
Corporate
Development
Key ESG Topics in this Chapter
Standardized Governance
Internal Control, Compliance and Risk Management
Business Ethics
SDGs Addressed
Information Security Protection
Pharmacovigilance
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 11
Standardized Governance 2025 Performance
Shareholders’ Meeting
general meetings of
•The Company convenes and holds general meetings of shareholders in shareholders
Governance Structure strict accordance with the Company Law, the Rules for General Meetings of
Shareholders of Listed Companies, the Articles of Association, the Rules of 4
Procedure for General Meetings of Shareholders and other relevant
In accordance with the requirements of laws and regulations including the Company Law of the People’s Republic of China, the Securities provisions. It treats all shareholders equally, provides convenient conditions
Law of the People’s Republic of China and the Self-Regulatory Guidelines for Listed Companies of Shenzhen Stock Exchange No.2–Stan- for shareholders to attend general meetings, and ensures the full exercise
adopted proposals
dardized Operation of GEM Listed Companies, BioKangtai has established a well-defined and mutually constraining governance structure of shareholders’ rights.
composed of the general meeting of shareholders, the board of directors (with various special committees thereunder) and the management
team. The Company has formulated the Rules of Procedure for the General Meeting of Shareholders, the Rules of Procedure for the Board of
•In terms of the protection of minority shareholders’ rights and interests, 29
the Company fully listens to the opinions and suggestions put forward by
Directors and the Working Rules for the President, which specify the responsibilities, authorities, rules of procedure and decision-making
attending minority shareholders. When reviewing material matters affect-
procedures of the general meeting of shareholders, the board of directors and the management team, so as to ensure the standardized
ing the interests of minority investors, it conducts separate voting counting
operation of the Company.
for the voting results of minority investors, and no decision-making acts
impair the interests of minority shareholders.
General Meeting of Shareholders
Strategy Committee
Secretary of the Nomination Committee
Board of Directors
Board of Directors
Board of Directors
Remuneration and Evaluation Committee meetings of the Board of
Chairman of the Board •The Board of Directors consists of 7 directors, including 3 independent Directors
Audit Committee directors and 1 employee representative director. The number and compo-
President Pharmaceutical Safety Committee
sition of the Board of Directors comply with the provisions of laws, regula-
tions and the Articles of Association. The Board of Directors has established
an Audit Committee, a Nomination Committee, a Remuneration and Evalu-
ation Committee, and a Strategy Committee. Each committee has clear attendance rate of
responsibilities and performs its respective duties, providing professional directors
support and supervision for the decision-making of the Board of Directors
Securities Affairs Department
Finance Center
Human Resources Department
General Manager Office
Corporate Development Department
Public Affairs Department
Quality Management Center
Production & Operation Center
Biosafety Office
R&D Center
Marketing Center
International Business Division
Supply Chain Department
Pharmacovigilance Department
Audit Department
and effectively improving the Company’s governance efficiency.
%
•The backgrounds of the Company’s directors cover diversified fields such
as industry and operation management, risk management, financial
accounting, etc., with differentiated educational backgrounds, professional
adopted proposals
experiences, skills and age structures. Such diversity ensures multi-dimen-
sional perspectives and complementary advantages in key areas including
strategic planning, risk management and control, and innovative develop-
ment, laying a solid foundation for scientific decision-making and sustain-
able development.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 12
Investor Rights Protection
Investor Communication Information Disclosure Management Shareholder Returns
The Company formulates and implements the Information Disclosure The Company has formulated and improved the Information Disclosure While promoting its own development, the Company has formulated a scien-
Management System and the Investor Relations Management System to Affairs Management System, the Inside Information Insider Registration tific and stable profit distribution policy based on its actual development and
carry out investor relations management and information disclosure in an Management System, the Information Disclosure Suspension and Exemption future development plans, and actively repays shareholders through continu-
orderly manner, treats all investors equally, and fully safeguards the legitimate Affairs Management System and other systems, and established a systematic ous cash dividends. In June 2025, the Company implemented the 2024 annual
rights and interests of investors such as the right to information. information disclosure management system to ensure the truthful, accurate, equity distribution, with a cash dividend of 101 million yuan, accounting for
complete, timely and fair delivery of information. During the reporting period, 49.85% of the net profit attributable to shareholders of the listed company in
The Company focuses on building a professional investor relations manage-
there were no false records, misleading statements, material omissions or 2024. For the 2025 fiscal year, the Company plans to distribute a cash
ment and value communication system, and unblocks two-way communica-
other improper disclosures in the Company’s information disclosure, dividend of 0.35 yuan per 10 shares (tax included) to all shareholders, with a
tion channels in the capital market. Through diversified communication
effectively protecting the legitimate rights and interests of investors. With total proposed cash dividend of 39.0925 million yuan (calculated based on
channels including the official website, hotline, e-mail, Hudongyi platform,
high-standard information disclosure requirements and practices, the the share capital as of March 31, 2026), accounting for 55.58% of the net
general meetings of shareholders, performance briefings, analyst meetings,
Company was awarded the highest rating – Grade A – in the 2024–2025 profit attributable to shareholders of the listed company in 2025. The
roadshows, reception of visits and seminars, the Company conducts open
Information Disclosure Evaluation of Shenzhen Stock Exchange Listed dividend plan is subject to deliberation and approval by the general meeting
and transparent communication with investors, conveys the Company’s
Companies released by the Shenzhen Stock Exchange. of shareholders before implementation. Since its listing, the Company has
strategic value and growth logic, and enhances investors’ value recognition.
accumulated cash dividends of 1.925 billion yuan (including the proposed
listed company.
Executive Compensation Management
The Remuneration and Evaluation Committee of the Company’s Board of Directors is responsible for formulating the Remuneration Management System for Directors and Senior Management,
which has been deliberated and adopted by the Board of Directors and the general meeting of shareholders. The system stipulates that executive compensation consists of basic salary, perfor-
mance-based salary, insurance and benefits, medium and long-term incentive income, etc., which are comprehensively determined based on factors such as the Company’s operating conditions,
job responsibilities, personal capabilities and performance appraisal. Among them, the proportion of performance-based salary shall in principle not be less than 50% of the total amount of basic
salary and performance-based salary, and a certain proportion of performance-based salary shall be withheld to determine the actual payable proportion and complete payment after the
disclosure of the annual report and performance evaluation based on the performance appraisal results. Performance evaluation is conducted based on audited financial data, which closely
integrates personal interests with the interests of shareholders and the Company, so as to motivate the core team and improve operating efficiency.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 13
Compliance and Risk Management
Compliant Operation Risk Management
The Company upholds the compliance philosophy of “Compliance Starts from The Company has formulated the Risk Management and Internal Control System Manual and established the “Three Lines of Defense” risk governance structure. It timely identifies
Senior Management, Voluntary Compliance by All Employees, and Compli- and systematically analyzes internal and external risks in business activities, and develops a risk management inventory.
ance Creates Value”. It has formulated the Compliance Management System
to regulate compliance management practices, established a compliance
First Line of Defense: Second Line of Defense: Third Line of Defense:
management team, and incorporated the effectiveness of compliance
All departments and subsidiaries Comprehensive Risk Management Office Comprehensive Risk Management Leading Group
management into the performance appraisal of senior management, depart-
ment heads and employees. In addition, the Company actively fosters a
compliance culture through organizing compliance training, distributing
•Identify risks in daily business activities, •Organize the collection of various •Formulate the overall objectives of risk
compliance manuals, signing compliance commitment letters and other
and assess and report identified risks; internal and external risk information; management, and determine the Compa-
means, establishes the values of law-abiding compliance and integrity, and
ny’s risk appetite and risk tolerance;
•Implement approved risk response plans •Organize risk assessment, formulate
consolidates the ideological foundation for compliant operation.
and timely feedback on risk response and risk management strategies, and super- •Review and approve the risk assess-
resolution results; vise the implementation of various risk ment results and solutions for major
controls; matters, as well as the annual comprehen-
•Monitor identified risks, conduct reassess-
sive risk management work report.
ment when changes occur, and take corre- •Regularly report risk management
Key Performance
sponding measures based on newly identi- information to the Risk Management
Number of employees Total hours of Number of compli- fied and assessed risk levels. Leading Group and compile the compre-
receiving compliance employee compliance ance training hensive risk management report.
training training sessions organized
by the Company
Tax Payment in Accordance with the Law
The Company strictly abides by the Tax Collection and Administration Law of the People’s Republic of China, the Implementation Rules for the Tax Collec-
tion and Administration Law of the People’s Republic of China and other relevant provisions, exercises strict control over tax-related work, standardizes
the management of tax payment matters, invoice management, tax file management and other work, reduces tax risks and ensures tax compliance.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 14
Business Ethics
Supervision Over Commercial Partners
Against Corruption and Bribery
The Company signs the Promoter Compliance Commitment Letter and the
Promoter Employee Compliance Commitment Letter with its promoters, explic-
Anti-Commercial Bribery and Anti-Corruption itly requiring promoters of Kangtai Minhai and their employees not to conduct
any commercial bribery acts. Meanwhile, the Company clearly stipulates in the
BioKangtai has formulated the Anti-Commercial Bribery Compliance Manual and the Detailed Rules for the Implementation of Clean Office Work. The Internal Audit Department is responsi- Regional Promotion Service Contract signed with promoters that promoters
ble for the administration and implementation of relevant work, and the senior management supervises and administers the Company’s anti-corruption work. Meanwhile, the Company shall comply with the Anti-Unfair Competition Law of the People’s Republic of
opposes all forms of corruption and bribery, imposes standardized requirements on all employees and partners in terms of professional integrity, and adopts a zero-tolerance policy toward China, the Interim Provisions on Prohibition of Commercial Bribery and other
unethical commercial practices. In 2025, the Company organized warning education and training for procurement personnel, covering content related to legal risks. laws and regulations, and that promoters and their staff within their responsible
market areas shall not commit any illegal or irregular improper acts such as
explicit or implicit rebates, brokerage fees, cash, marketable securities, shop-
Whistleblowing Hotline：0755-26988630
or departments such as health and disease prevention and control institutions
Total number of employees receiving Number of anti-corruption and their staff.
anti-corruption training training sessions
The Company holds relevant compliance training for the promoter team every
Whistleblowing Email：shenjibu@biokangtai.com year, requires them to sign agreements with integrity clauses, and establishes a
series of behavior supervision and administration mechanisms for guarantee. In
addition, the Company conducts compliance investigations on key commercial
partners, and departments with inadequate implementation shall be dealt with
Anti-Monopoly and Fair Competition Whistleblowing Management Mech-
in accordance with the system and internal provisions.
anism and Whistleblower Protection
The Company strictly abides by the Anti-Monopoly Law of the People’s Republic of China, The Company has formulated the Whistleblowing Management System, under which the
the Anti-Unfair Competition Law of the People’s Republic of China and global competition Audit Department is responsible for the administration and implementation of whistleblow-
compliance standards, and has established an anti-monopoly compliance management ing matters. The Company has established whistleblowing channels for internal and exter-
system covering the entire business process. It firmly eliminates acts such as monopoly nal stakeholders and undertakes to keep whistleblowers’ personal information and report-
agreements, abuse of dominant market position, and failure to declare concentration of ing materials strictly confidential, severely cracking down on any retaliatory acts and impos-
undertakings in accordance with the law. The Company adheres to the cooperative princi- ing strict accountability in accordance with relevant Company regulations upon verification.
ples of openness, transparency and non-discrimination, does not impose unreasonable When receiving whistleblower calls, emails, letters or receiving visiting entities and individu-
transaction restrictions on partners or implement exclusive and discriminatory arrange- als, the Company shall carefully listen to whistleblowers’ statements, inquire about their
ments, ensures equal participation of upstream and downstream entities in market names, addresses, telephone numbers, reported subjects and details of reported matters,
competition, and safeguards the legitimate rights and interests of consumers and small and keep detailed records. After acceptance of a reported matter, the Audit Department
and medium-sized partners. Meanwhile, the Company actively fosters a business culture organizes corresponding project initiation, investigation, handling and reporting. The
of integrity, compliance and sound competition through regular compliance training, risk Company maintains communication and contact with whistleblowers during investigations;
self-inspection, supervision and accountability, and promotes the healthy development of meanwhile, upon approval of the investigation report, the resolution result shall be
the industry with high-standard competition governance. feedback to whistleblowers within five working days, and a dedicated person shall super-
vise relevant responsible departments or personnel to implement the handling opinions.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 15
Information Security Category Control Item Content
Protection
• The Company adopts TLS version 1.2 or above to encrypt data transmitted over the network, so as to prevent the risk of
Encrypted
man-in-the-middle attacks.
Transmission
and Storage • The Company deploys file encryption on terminal devices including laptops, desktop computers and USB flash drives to
ensure that data cannot be read in the event of physical medium loss.
The Company strictly complies with the Cybersecurity Law of the People’s • The Company implements a role-based access control policy, configures data and system access permissions according to
Access
job responsibilities, and applies the principle of least privilege.
Republic of China, the Data Security Law of the People’s Republic of Control
Technical • The Company establishes a periodic permission review mechanism to promptly revoke or adjust unnecessary authorizations.
China and other laws and regulations. It has formulated the Computer- Protection
ized System Security Management Procedures, Data Classification and
Data Leakage • The Company deploys online behavior management and data leakage prevention systems to conduct content audit and
Grading Management System, Network and Information System Emer- Prevention abnormal behavior blocking on information such as outgoing emails, instant messages and file transfers.
gency Plan, Personal Information Confidentiality System and other docu-
• The Company implements transparent encryption management for sensitive files. Files are automatically encrypted once
ments, and assigned 2 full-time information security personnel to build a File Encryption
leaving the authorized internal environment of the enterprise and cannot be decrypted without authorization.
comprehensive information security management system from five
“
aspects: organization, management, technology, training and supervi-
sion. As of the end of the reporting period, the Company has obtained
Class II cybersecurity protection certification for its official website,
human resource system, Caidie QMS system, LIMS laboratory manage-
ment system, EMS BMS system and ERP system.
Category Management Link
Data Collection
Data Usage
•
•
Specific Control Requirements
The Company adheres to the principle of data minimization and only collects personal information directly relevant to
business purposes to avoid excessive collection of users’ private data. The Company implements confidential management
of all data.
The Company prohibits the export of business data stored in systems to unauthorized terminal devices or external email
Management accounts. All data-related operations are recorded in audit logs to ensure traceability.
Specifications
• In accordance with data classification and grading policies and retention period requirements, the Company sets automat-
Data Destruction
ic cleaning rules for user information and conducts secure deletion upon expiration.
Category Control Stage Specific Management Requirements
In-service • All employees are required to sign confidentiality agreements and non-compete agreements upon onboarding and
Training complete specialized training on information security and confidentiality awareness.
Onboarding • The Company regularly conducts information security awareness promotion and professional skill training. It implements
Training background checks and more frequent security capability assessments for key position personnel.
Personnel
Management
• The Company implements a standardized offboarding audit process to ensure that system accounts and permissions of
Offboarding
departing employees are fully revoked before the effective date of resignation. It reiterates employees’ confidentiality
Audit
obligations and legal liabilities during employment through exit interviews.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 16
Pharmacovigilance Full-Cycle Pharmacovigilance Management
The Company monitors, analyzes, identifies, assesses and controls risks in clinical research and post-marketing application of products, and formulates
corresponding response measures for risks in different links.
Link Measures
Governance
In accordance with the Pharmaceutical Administration Law of the People’s Republic of China, the Vaccine
Clinical Research ?Establish management procedures for clinical pharmacovigilance to regulate pharmacovigilance work
Administration Law of the People’s Republic of China, the Good Pharmacovigilance Practice and other laws
Pharmacovigilance in clinical trials of products.
and regulations, Shenzhen Kangtai Biological Products Co., Ltd. has established a Drug Safety Committee
composed of heads of relevant departments, with the President serving as Director and the Pharmacovigi-
lance Officer as Executive Director. The Company has established and improved a pharmacovigilance system
Post-Marketing Risk ?Formulate the Pharmacovigilance Plan, monitor the occurrence of AEFI in real time, and conduct
to ensure its dynamic adaptation to regulatory updates and internal development needs. It has set up an
Identification, Assessment vaccine safety risk assessment.
independent Pharmacovigilance Department directly managed by the Pharmacovigilance Officer and
and Control
reporting to the President. A professional pharmacovigilance data management system has been deployed
to realize electronic, standardized and regulated operation of pharmacovigilance workflows.
?Actively expand information collection channels, collect AEFI during the use of vaccines produced by
the Company through telephone follow-ups, on-site visits and other means, and conduct monitoring
Strategy Post-Marketing AEFI
and management in accordance with procedures;
Monitoring and Reporting
The Company regards pharmacovigilance management as a core mission to protect public drug safety. It ?Introduces and applies a pharmacovigilance data management system to collect and manage AEFI
adheres to regulatory requirements as the benchmark and ensures that all relevant personnel fully perform reports in the clinical trial stage and post-marketing AEFI information.
pharmacovigilance duties and effectively participate in the whole-process management. By efficiently
utilizing drug safety information, the Company scientifically carries out risk identification, analysis and
control, and continuously maintains the risk-benefit balance of vaccines. It conducts active monitoring, rapid
assessment and coordinated disposal of adverse reactions following vaccination, effectively prevents and Pharmacovigilance Training
reduces potential risks, and maximizes the protection of patients and public health.
With “protecting patient safety” as the core goal of pharmacovigilance, the Company has formulated the Pharmacovigilance Management Training Proce-
dures. It carries out systematic training for full-time pharmacovigilance personnel and non-full-time pharmacovigilance personnel (covering all employees)
Impact, Risk and Opportunity Management in accordance with the Annual Training Plan, so as to strengthen the stable operation of the pharmacovigilance system. In addition, the Company conducts
at least one training session on the collection and management of Adverse Events Following Immunization (AEFI) every year. Through such training, employ-
The Company has established a multi-channel mechanism for the collection and management of Adverse
ees can gain an in-depth understanding of AEFI monitoring and reporting knowledge, and improve their awareness and capability of reporting safety
Events Following Immunization (AEFI). Information sources include the National Adverse Drug Reaction
information.
Monitoring System (direct reporting system), feedback from regulatory authorities, the 400 service hotline,
the frontline sales network, and domestic and international literature retrieval. For risk assessment, the
Company implements a dual mechanism: on the one hand, it conducts signal detection for each AEFI report
Indicators and Targets
to identify potential risk signals; on the other hand, it carries out a comprehensive assessment every six
months to ensure early risk identification and response. Meanwhile, the Company actively cooperates with
centers for disease control and vaccination institutions to assist in communication on individual adverse The core objective of the Company’s pharmacovigilance management is to ensure the rational use and controllable risks
reaction cases. For cases involving compensation, it implements relevant provisions through commercial of vaccines. During the reporting period, no new risks requiring special control measures were identified, and the
insurance. It strictly complies with the time limits of national monitoring plans and submits reports by level to marketed vaccine products demonstrated good safety profiles.
ensure the whole process is compliant and controllable.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 17
Efficient
Operations for
Green and
Sustainable
Development
Key ESG Topics in this Chapter
Climate Change Response
Environmental Compliance Management
Pollutant Emission and Waste Disposal
SDGs Addressed
Resource Utilization and Circular Economy
Biodiversity Conservation
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 18
Climate Change Response Governance
The Company has established a top-down sustainable development management mechanism, formed a full-time team with professional knowledge, skills, industrial
background and experience, and regularly conducts special training to ensure the organization is capable of promoting climate change adaptation, energy conservation and
To disclose the Company’s climate change response work in a scientific and effective manner, emission reduction and other related work.
the Company follows the recommendations of the Task Force on Climate-related Financial
Disclosures (TCFD) and discloses its climate change risk management system and response Level Composition Responsibilities
actions from four dimensions: governance, strategy, risk management, and indicators and
targets.
Board of Directors / Strategy
• Responsible for reviewing the disclosure of climate-related information in the ESG Report.
Committee of the
Decision-Making Level
Board of Directors
st
rn
ra
ve
te
go
gy
• Responsible for collecting the Company’s carbon emission information and energy conservation
ESG Working Group
and emission reduction measures, and disclosing relevant information in the ESG Report.
Management Level
four-dimension
ris k
als
ma
Go
na
• Responsible for the concrete implementation of energy conservation and emission reduction
nd
m
ge
en a
t rs Relevant Departments projects, cooperating with the ESG Task Force to provide carbon emission-related information
ca to
In di Implementation Level and reviewing the accuracy of such information.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 19
Strategy
In light of forward-looking global trends, the Company conducts multi-dimensional qualitative analysis to identify potential risks such as stricter policies and regulations, accelerated technological substitution, shifting market preferences and insufficient supply
“
chain resilience. Meanwhile, the analysis covers key links including corporate operations (energy use, production processes), supply chain management (supplier carbon performance, recycled material substitution) and the full product life cycle (design, manufac-
turing, recycling).
Risk Type Risk Name Financial Impact Time Horizon Likelihood Scope of Impact Response Measures
Extreme weather events • Establish an emergency management mechanism and a diversified
Upstream value chain (produc-
Short-Term Risk (earthquakes, floods, Cost Increase Medium, Long Term High supply chain layout to mitigate the impact of sudden disasters on
tion and logistics)
typhoons, etc.) production and logistics.
Physical Risk
•Invest in energy-saving technologies and circulating water systems
Upstream value chain, corporate to optimize energy and water use efficiency.
Long-Term Risk Sea level rise, water scarcity Cost Increase Long Term High
operations •Promote renewable energy substitution to reduce operational
carbon footprint and energy costs.
Stricter carbon •Promote energy efficiency improvement and equipment renovation
tax/cap-and-trade policies, Upstream value chain, corporate to optimize energy efficiency.
Policy Cost Increase Short, Long Term High
upgraded environmental operations
•Increase the proportion of renewable energy use.
regulations
Higher green production
•Increase R&D on green technologies and optimize production
Technology standards, stricter environmen- Cost Increase Long Term High Corporate operations
processes to reduce energy consumption and emissions.
tal technology requirements
Transition Risk
Customer preference for • Proactively adapt to global carbon footprint standards and advance
Revenue
Market low-carbon procurement, Medium, Long Term Medium Downstream value chain green and low-carbon transformation to ensure product market
Reduction
higher bidding thresholds access and align with market preferences.
• Strengthen sustainable management and information disclosure to
Damage to brand reputation, Revenue
Reputation Long Term Low Downstream value chain maintain brand reputation and safeguard long-term corporate
which further affects corporate Reduction
sustainable development value.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 20
Opportunity Factor Impact Scenario Financial Impact Time Horizon Likelihood Scope of Impact Response Measures
Subsidies for renewable energy, fiscal support Increased green investment and financing
Policy Opportunity Medium Term High Corporate operations • Proactively apply for government subsidies and tax incentives.
for energy-saving technological transformation opportunities, policy subsidy support
Application of energy-saving technologies, intelli- • Implement an energy management system and conduct regular
Efficiency Opportunity Decreased operational costs Long Term Medium Corporate operations
gent energy management energy efficiency audits.
R&D of thermostable vaccines, innovation of
Product Opportunity Business revenue growth Medium Term Medium Global market • Increase R&D investment and expand space in emerging markets.
low-carbon vaccines
Financial Opportunity Green credit, rising preference for ESG investment Reduced financing costs, expanded Medium Term Medium Corporate operations • Improve ESG performance.
funding channels
Impact, Risk and Opportunity Management Indicators and Targets
The Company has established a systematic identification and assessment process to comprehensively examine the impacts, risks and opportunities of climate The Company integrates sustainable development into its core strategy and has set clear low-carbon strategic
change on business operations. objectives.
Identification Assessment Monitoring Response
• Identify climate risks and • Evaluate the applicability • Conduct continuous • Develop response plans
Direct (Scope 1) Greenhouse Energy Indirect (Scope 2)
opportunities based on its and importance of various stakeholder communica- based on risks and
Gas Emissions Greenhouse Gas Emissions
own production and risks and opportunities in tion and regular reassess- opportunities, including
operation status, light of actual business ment to ensure that but not limited to Metric tons of Metric tons of
combined with industrial conditions, and compre- relevant risks, opportuni- formulating a low-carbon CO₂ equivalent CO₂ equivalent
development trends, hensively determine the ties and response transformation plan and
domestic and foreign risk levels and material measures are suitable for adopting a series of
policy environments and opportunities from the the Company’s actual adaptation measures
Greenhouse Gas Emission Greenhouse Gas Emission
benchmarking of perspectives of occur- situation. upon approval by the
Intensity Reduction
advanced practices, and rence probability, business management.
form an inventory. development, financial Metric tons of CO₂ equivalent / Metric tons of
impact and reputation Operating Revenue or Sales CO₂ equivalent
impact.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 21
Environmental Compliance Management
Key Performance
Environmental Compliance Governance
The Company strictly abides by the Environmental Protection Law of the People’s Republic of China and other relevant legal provisions,
During the reporting period
and has formulated systems such as the Environmental Protection Management Procedures and Environmental Aspects and Hazard
Identification and Control Procedures, which stipulate environmental monitoring, environmental information declaration, environmental
emergency response and other contents to standardize environmental behaviors and reduce pollutant emissions.
Agreed electricity volume, Can reduce carbon dioxide The quantity of green certificates
green electricity emissions by approximately purchased by Kangtai Biotech The Company’s EHS Committee serves as the environmental protection management body, with the Safety and Environmental Office
under it responsible for daily environmental management. The Company requires all employees to sign EHS target responsibility letters,
and links environmental management performance to the quarterly performance appraisal of middle and senior management. Mean-
while, the Company has formulated the Emergency Plan for Environmental Emergencies to improve the emergency response mechanism
for environmental emergencies; through environmental protection training, it continuously enhances employees’ environmental manage-
ment awareness and professional capabilities. During the reporting period, the Company and its subsidiaries did not receive any adminis-
trative penalties for violations of environmental protection laws and regulations. As of the end of the reporting period, Shenzhen Kangtai
Biological Products Co., Ltd. and BioMinhai had obtained ISO 14001 environmental management system certification.
Case
During the reporting period
BioMinhai Won the Title of “Beijing Low-Carbon Leader”
Carry out environmental emergency drills Completion rate of environmental hazard rectification
In 2025, the Beijing Municipal Ecology and Environment
Bureau officially released the annual list of “Beijing
Low-Carbon Leader” enterprises (6 in total). BioMinhai was
successfully selected for the list with its outstanding perfor-
mance in green manufacturing, energy conservation and
Case
carbon reduction, becoming the only enterprise in Daxing
District to receive this honor in the year, further consolidat-
ing its leading position as a benchmark for low-carbon Organizing Environmental Protection Training
development in the biopharmaceutical industry.
The Company enhances employees’ environmental management awareness and
professional capabilities through environmental protection training. During the
reporting period, the Company carried out training including Solid Waste Manage-
ment Training and General Industrial Solid Waste Training, and organized environ-
mental engineers to participate in the Shenzhen Environmental Protection Director
Competence Improvement Assessment held by the Shenzhen Municipal Bureau of
Ecology and Environment, who obtained qualified certificates.
Solid Waste Management Training
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 22
Cleaner Production Biosafety
The Company actively promotes green processes, such as improving the ethanol application process for multivalent vaccines to reduce The Company has established a Biosafety Committee that strictly follows national standards including the general requirements for
solvent consumption, and adopting advanced testing methods such as nuclear magnetic resonance to replace part of traditional pathogenic microorganism laboratories, formed a complete system of institutional documents, and formulated and implemented biosafe-
reagents. BioKangtai Biological Products Co., Ltd. has been awarded the title of “Shenzhen Green Enterprise”, and BioMinhai has won the ty risk assessment rules. Risk assessment is conducted before the introduction or use of pathogenic microorganisms, covering environ-
national-level “Green Factory” and “Beijing Green Factory” titles. mental sensitivity, pathogenicity, prevention and treatment conditions, hardware facilities and other aspects, with the commitment to
achieving “zero accidents” in biosafety management. Specific measures include preventing personnel exposure, controlling waste gas and
wastewater discharge to meet standards, and ensuring no pathogenic microorganism leakage or infection incidents. As of the end of the
reporting period, all indicators of the Company have been achieved, all testing results over the years are qualified, and no safety incidents
Case have occurred.
Measure Content
BioMinhai Awarded “National Green Factory”
• Laboratories adopt directional airflow design; waste gas is discharged after multi-stage
In 2025, the Ministry of Industry and Information Technology
Hardware Support high-efficiency filtration, and filter materials are regularly replaced and inspected.
of the People’s Republic of China released the 2024 Green
Manufacturing List. After rigorous review and multi-level
• Operators are equipped with disposable protective clothing, and sterilizable reusable
selection, BioMinhai was successfully awarded the honorary Personnel Protection
protective equipment is used in key operation areas.
title of “National Green Factory” for its outstanding perfor-
mance in green manufacturing, energy conservation, emission
• All items taken out of the operation area must be disinfected. Infectious waste is sterilized
reduction and sustainable development. This represents the Waste Disposal
at high temperature and pressure before being handed over to qualified third-party
highest recognition for the Company’s commitment to build-
institutions for disposal.
ing an environment-friendly and resource-conserving enter-
prise. • Laboratory wastewater is transported through pipelines to an inactivation system, inacti-
vated by heating or chemical methods (such as alkalization, chlorine-containing
disinfectants) according to the characteristics of pathogenic microorganisms, and
Wastewater Treatment
BioMinhai Won the Honor of “Five-Star Green Credit Enterprise” discharged to the sewage station for further treatment after passing verification, before
finally entering the municipal pipe network.
In 2025, at the “Daxing District · Langfang City World Environment
Day Main Event”, BioMinhai once again won the honor of “Five-Star
• Emergency plans for various scenarios are formulated, and at least one comprehensive
Green Credit Enterprise” for its excellent performance in the Emergency Preparedness
emergency drill is organized every year.
construction of the green credit system. This is the fourth consecu-
tive year that the Company has received this environmental honor
since 2022, highlighting its benchmark status in the coordinated Key Performance
environmental development of the Beijing-Tianjin-Hebei region. The
“Five-Star Green Credit Evaluation” conducts stringent assessment
from five dimensions: environmental compliance, energy conserva- During the reporting period The inactivation rate of laboratory waste is
tion and emission reduction, resource recycling, management
innovation and social responsibility. 100 %
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 23
Pollutant Emission and Waste Disposal
The Company strictly abides by the Law of the People’s Republic of China on the Prevention and Control of Air Pollution, the Law of the People’s Republic of China on the Prevention and Control of Water Pollution and the Law of the People’s Republic of China on
the Prevention and Control of Environmental Pollution by Solid Waste, and has formulated the Solid Waste Management System, the Workshop Drainage Management System and the Waste Gas Emission Management System. The EHS Committee acts as the adminis-
“
trative body, and the Safety and Environmental Protection Office is responsible for daily administration. Meanwhile, the Company regularly organizes special training such as Solid Waste Management Training and Hazardous Waste Management Training to continuous-
ly strengthen employees’ environmental awareness and professional competence. In terms of operation monitoring, the Company adopts a combination of manual monitoring and automatic monitoring to ensure that all pollutants are discharged up to standards.
Wastewater Management Waste Gas Management
Generation Sources Generation Sources
Mainly domestic sewage and production wastewater. Volatile organic waste gas generated in the production process, volatile organic waste gas generated in R&D and quality
inspection experiments, malodorous waste gas from animal rooms and sewage treatment stations, flue gas from boiler
rooms, catering waste gas from canteens, etc.
Monitoring Indicators
COD, ammonia nitrogen, total nitrogen, pH, total phosphorus, etc. Monitoring Indicators
Non-methane total hydrocarbons, acetone, phenols, odor concentration, canteen oil fumes.
Management Objective
Strictly comply with national standards, with a 100% compliance rate of wastewater discharge. Management Objective
Treatment Methods Strictly comply with national standards, with a 100% qualified rate of waste gas emission.
•Production wastewater and pretreated domestic sewage are discharged into the sewage treatment station, and discharged
Treatment Methods
into the municipal sewage pipe network after treatment up to standard; clean water enters the reclaimed water station for
advanced treatment, part of the effluent from the reclaimed water station is reused for greening in the plant area, and the •High-efficiency filters + activated carbon adsorption are adopted for volatile organic waste gas.
rest is discharged to the main wastewater outlet of the plant area. •Ion deodorization + activated carbon adsorption are adopted for waste gas from the sewage treatment station.
•An online wastewater monitoring system is installed to monitor the indicators in wastewater in real time; a third party with •Integrated turbulent spray deodorization is adopted for waste gas from animal rooms.
CMA qualification is entrusted to sample and test wastewater in accordance with the requirements of the pollutant
•Mechanical-electrostatic composite oil fume purifiers are adopted for catering waste gas.
discharge permit.
•The sewage treatment station adopts the treatment process of “collecting tank + grid + regulating tank + biological oxida-
tion + disinfection”.
•A professional environmental protection engineering unit is entrusted to be responsible for the operation and management
of the sewage treatment station, conduct daily safety inspections of sewage treatment facilities in the plant area, and
promptly follow up on fault handling.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 24
Solid Waste Management
Generation Sources
Case
General industrial solid waste includes waste packaging materials of raw and auxiliary materials, waste filter media for pure
Emergency Drill for Organic Solvent Leak-
water/soft water preparation, etc.; hazardous waste includes waste drugs, waste organic solvents, waste chemical reagents,
laboratory waste liquid and other hazardous wastes generated in operation.
age in Hazardous Waste Warehouse
In November 2025, BioKangtai carried out an emergency
Monitoring Indicators
drill for organic solvent leakage in the hazardous waste
warehouse. The drill aimed to improve on-site operational
•For general industrial solid waste, the total annual generation volume and recyclable utilization rate are tracked.
proficiency of personnel and the coordinated combat
•For hazardous waste, characteristic indicators such as toxicity, corrosivity and flammability are tracked by hazardous waste
capability of all departments in emergency response and
category.
disaster relief from three aspects: operation specifications,
emergency disposal and risk awareness. 固体废弃物管理培训
Management Objective
Emergency Drill for Organic Solvent Leakage
waste leakage, 100% legal disposal rate of hazardous waste.
Treatment Methods
Indicator 2025 Performance
General industrial solid waste Hazardous waste
Total Wastewater Discharge 1,196,225.064 Cubic meter
•After centralized collection, it is recycled by
material recycling companies; non-recyclable
•All departments collect and transfer it to the Safety, Fire
Protection and Energy Office, which contacts companies with Total General Solid Waste 116.604 Ton
waste is regularly cleared and disposed of by the hazardous waste disposal qualifications for transshipment
sanitation department. and treatment. The hazardous waste temporary storage room
meets safety requirements such as leakage prevention, fire
Total Hazardous Waste 254.211149 Ton
prevention and explosion prevention, and is equipped with
corresponding emergency supplies.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 25
Resource Utilization and Circular Economy
Energy Utilization
Governance Strategy Impact, Risk and Opportunity Management
In accordance with the Energy Conservation Law of the People’s Republic of China, Energy Management The Company fully taps the energy-saving potential of all links by establish- The Company regularly entrusts third-party institutions to conduct energy audits to
Systems—Requirements with Guidance for Use and other laws and regulations, the Company has established ing a systematic action plan covering improved metering, equipment fully understand its energy management level and energy consumption status,
an Energy Management Committee with an energy management team under it. The team is headed by the elimination, process optimization and behavior standardization. By incorpo- identify problems and weak links in energy utilization, tap energy-saving potential,
production director and composed of personnel from various departments, and has formulated the Energy rating energy conservation and consumption reduction into performance seek energy-saving directions, reduce energy consumption and production costs,
Management System to standardize energy management. Meanwhile, the Company has formulated systems appraisal and cultural construction, the Company guides all employees to and improve corporate economic benefits.
such as the Energy Reward and Punishment Regulations, integrating energy management and energy conser- participate in technological innovation and process improvement. Relying
vation into performance appraisal. It attaches great importance to the cultivation of employees’ energy conser- on regular supervision, inspection and reward-punishment mechanisms, it
vation awareness and carries out training on warehousing energy conservation measures, energy control imple- continuously improves energy utilization efficiency, reduces operating costs
mentation plans and other contents. As of the end of the reporting period, the Company had obtained ISO and consolidates the foundation for green factory construction.
Key Practices of Energy-Saving Technologies
Project Name Operation Status and Effect
•Thermal insulation is applied to high-temperature equipment and pipeline systems in the water
Thermal Insulation of High-Tem-
perature Equipment and Facilities preparation workshop using steam, with customized soft detachable insulation blankets to
reduce heat loss.
• The boiler heats fresh water by using flue gas waste heat; the water vapor from the deaerator is
Waste Heat Recovery
heated by the flue gas temperature through an energy saver.
• In winter, the refrigeration station adopts natural cooling through plate heat exchangers, using
Refrigeration Station /
Cold Source System low-temperature cooling water to cool chilled water without starting chiller units, greatly reduc-
ing system energy consumption and operating costs.
•Adopted an integrated intelligent equipment control system for chilled water.
Equipment Renewal and
Energy-Saving Technological •Replaced with new energy-saving air conditioning systems, saving 25,800 kWh per year;
Transformation •Replaced with new energy-saving air compressors, saving 175,200 kWh per year.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 26
Digital Management Indicators and Targets
BioKangtai Biological Products Co., Ltd. implements energy management and control by establishing a regular energy use reporting mechanism, issuing monthly reports on natural
gas and electric energy consumption, and requiring all departments to formulate energy management and control plans.
Based on the four thematic functions of “safety precaution, green energy conservation, high efficiency and convenience, and comfort and health”, BioMinhai has constructed Indicator 2025 Performance
application scenarios to fully activate data resources and realize intelligent empowerment. Through the construction of an integrated management platform for the smart park, it
has innovatively integrated technologies and intelligent equipment such as BIM, GIS, IoT and AI. Through data perception, transmission analysis and application research, it has
built a “platform + application” intelligent service for park operation and management, completed 13 intelligent scenarios and 55 intelligent functions in the park, and realized
intelligent management and control of the park. Natural Gas 9,168,715 Cubic meter
Steam 212,587.21 Cubic meter
Diesel Oil 79,780 Liter
Gasoline 24,190 Liter
Renewable Energy 36,532,400 kWh
Purchased Electricity 95,956,240 kWh
Use of Clean Energy
BioMinhai has installed 142 sets of solar water heaters in the dormitory buildings of
the South Plant to provide bathing hot water for employee dormitories. The heat
collection area of each set of solar water heater is 3.11 m?.After calculation：
Annual electricity savings
of solar water heaters standard coal
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 27
CASE
Water Resource Utilization
“
The Company’s water source is municipal tap water, which is not used as
a major consumable resource in the production process, resulting in a low
risk of water shortage. As of the end of the reporting period, BioMinhai
had been awarded the title of “Beijing Water-Saving Enterprise”.
Leading a Green Lifestyle by Scientific Water Use
In December 2025, the themed publicity activity “I Speak for Water Conservation” co-sponsored by the
Beijing Water Authority, Daxing District Water Authority, Environmental Protection Section and BioMinhai was
held at the International Industrial Base of BioMinhai. The activity integrated water conservation knowledge
Q&A into fun sports through challenge games such as “Water Conservation Ball Rolling”, knowledge ring toss
and pitch-pot; meanwhile, on-site quizzes were organized to deepen employees’ understanding of the
current water resources situation and relevant policies, and “I Speak for Water Conservation” initiative videos
were shot to expand communication via new media. As a biopharmaceutical enterprise rooted in Beijing,
BioMinhai has enhanced employees’ environmental awareness in an entertaining way. In the future, it will
continue to join hands with all sectors of society to innovate publicity forms and contribute to the construc-
tion of a sustainable development city with harmonious coexistence between humans and water.
Building a Joint Water Conservation Line to Protect the Source of Life
During the 38th “China Water Week”, with the theme of “Promoting High-Quality Water Conservancy Devel-
opment and Safeguarding National Water Security”, the Daxing District Water Authority and Environmental
Protection Section jointly launched a water conservation publicity campaign with BioMinhai. At the event
site, staff distributed promotional materials to employees, popularized water-saving tips and the current
situation of water resources, and conveyed the concept of “Every Drop at Your Fingertips, Water Conserva-
tion in Your Heart” to every participant. This activity was not only a knowledge popularization but also a call
for nationwide water conservation action. By building a publicity matrix of “government guidance + enter-
prise response”, BioMinhai promoted the implementation of the Code of Conduct for Civil Water Conserva-
tion, guided employees to internalize water conservation into a conscious lifestyle, and gathered nationwide
strength to protect water resources through small corporate actions.
Indicator 2025 Performance
Total Water Intake from All Regions 1,287.78102678 Megaliter
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 28
Circular Economy Biodiversity
The Company deeply integrates the concept of circular economy into its operations, implements a dual-track water resource recycling system (rainwater reuse and reclaimed water
reuse), widely adopts recyclable incubators for cold-chain transportation, and encourages employees to participate in conservation and recycling practices. It is committed to achieving Conservation
a full-chain closed loop from source reduction to end-of-life treatment and promoting sustainable resource utilization.
Key Practices of Circular Economy The Company adheres to the bottom line of biodiversity conservation in produc-
tion and operation, and proactively identifies, monitors and mitigates the
potential negative impacts of its operations on the surrounding ecology. The
New Vaccine International Industrial Base of BioMinhai deeply integrates
Rainwater Reuse System Reclaimed Water Reuse System Condensate Reuse System
cutting-edge biotechnology with natural ecology. Through natural lighting,
BioMinhai has built a rainwater collection and Wastewater generated in the pure water The air conditioning hot water unit has been ventilation systems and large-area vegetation landscapes including more than
reuse system. The collected and purified preparation process and bottle-washing modified from direct discharge to condensate 60 species such as arbors, shrubs, bamboo forests and flowers, it realizes the
rainwater is used for landscape water, with a wastewater enter the reclaimed water recovery. After treatment, the condensate is organic symbiosis between architecture and the environment.
designed daily treatment capacity of 180 m?/d. treatment station for treatment. The treated retransmitted back to the system, realizing
This water-saving technology has been includ- water is reused for toilet flushing, road sprin- resource recycling and saving about 35,000
ed in the Catalogue of Water-Saving Processes, kling, greening and underground garage tons of softened water per year.
Technologies and Equipment Encouraged by washing, with a designed daily treatment
the State (2023). capacity of 320 m?/d.
Indicator 2025 Performance
Total Recycled/Reclaimed Water 82,362 Megaliter
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 29
Synergy for a
Harmonious
Value
Ecosystem
Key ESG Topics in this Chapter
Employee Rights and Interests
Training and Development
Occupational Health and Safety
SDGs Addressed
Rural Revitalization and Social Public Welfare
Health and Medical Accessibility
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 30
Employee Rights and Interests
The Company strictly complies with the Labor Law of the People’s Republic of China, Labor Key Performance
Contract Law of the People’s Republic of China and other relevant laws and regulations,
and firmly rejects differential treatment of employees based on factors such as age, gender,
ethnicity, native place, religious belief and others. The Company attaches importance to
During the reporting period
cooperation with research institutes and universities, and recruits outstanding talents
through multiple channels such as online recruitment, headhunting services, campus
recruitment, internal referral and on-site recruitment. The Company strictly abides by The proportion of labor contracts signed
national and local laws and regulations regarding working hours, and implements a differ-
entiated working hour management system in light of the characteristics of different %
positions.
In addition, the Company strictly abides by the Law of the People’s Republic of China on the
Protection of Minors, the Provisions on Prohibition of Using Child Labor and other laws and
regulations, and commits to eliminating all forms of illegal labor practices, including but not
limited to human rights violations such as employing child labor under the age of 16, using
prison labor, forced labor, debt bondage and human trafficking.
Democratic Management
The Company advocates the labor governance values of diversity, equality and inclusiveness, and upholds the principle of equal pay for equal work. It establishes the work union which is
responsible for holding workers’ congresses to build a full-chain democratic management mechanism of “full participation + representative deliberation”, and regularly goes to the front
line to listen to employees’ voices. Led by the Chairman, the Company established an Employee Committee in 2025 as an important supplement to the workers’ congress. Meanwhile, focus-
ing on employees’ frequent concerns such as catering and accommodation, the Company has innovatively built an online-offline linked “Employee Feedback Collection Code” platform. It
collects employees’ demands by posting QR codes in prominent locations of high-frequency activity areas and pushing them to various online working groups.
Employee Satisfaction Survey
To fully understand employee engagement and the grassroots working environment, and by statistics
ensure the steady development of the enterprise on the basis of fully considering employ-
ees’ feelings and needs, the Company conducted an employee satisfaction survey in 2025
The overall satisfaction rate of this survey
covering all employees.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 31
Remuneration and Benefits Employee Care
The Company adheres to the distribution principle of “efficiency first, fairness consideration and distribution according to work”. It has formulated the Remuneration Manage- Care for Female Employees
ment Measures, Performance Management System and Remuneration Accounting Rules. The salary structure consists of basic salary, position-based salary, confidentiality
The Company provides a comfortable and convenient nursing environment for female
salary, performance bonus, allowances and subsidies, welfare expenses and special salary, forming a reasonable salary ladder distribution. The Company upholds the principle
employees during lactation and distributes maternity care gifts. It is equipped with
of two-way communication: department heads assess employees’ performance through performance appraisal forms, and employees may contact department heads for
professional venues such as yoga rooms and dance studios, and organizes body-shaping
feedback and appeal if they have doubts about the appraisal results.Under normal circumstances, the first appeal shall be filed with the immediate supervisor of the direct
activities including aerobics at least once a year. During International Women’s Day, the
supervisor. Upon receipt of the appeal, an investigation shall be conducted among the relevant parties involved, a handling opinion shall be put forward and submitted to the
Company holds special activities such as handcrafting and floral art appreciation, and
competent leader for ruling. If the applicant is dissatisfied with the decision on the first appeal, a further appeal may be filed to a higher level of the Company. If the applicant
distributes festival gifts to female employees.
still refuses to accept the ruling on the further appeal, a lawsuit may be filed to a labor dispute arbitration institution or a people's court.
The Company has formulated systems including the Remuneration and Welfare Management System, Welfare Management Measures and Five Insurances and One Housing
Fund Management Measures to continuously improve the welfare system. Meanwhile, the Company provides festival benefits covering all employees and their families,
CASE
including but not limited to traditional festivals such as the Spring Festival, Tomb-Sweeping Day, Dragon Boat Festival and Mid-Autumn Festival. It has improved the special
congratulatory gift system, such as wedding gifts for married employees and special grants for employees whose children are admitted to institutions of higher education.
Elegant Floral Charm · Salute to Her Strength
To celebrate International Women’s Day, the Corporate Culture Team of the
Company organized the themed handcraft activity “Elegant Floral Charm ·
Festival Benefits Salute to Her Strength” at the Guangming Base on March 7, attracting more
Statutory Benefits than 40 female employees. Taking traditional aesthetics as a bond, the activity
Women’s Day Gifts
integrated artistic creation with modern spirit, aiming to pay tribute to female
Endowment Insurance Medical Insurance
Birthday Gifts workers, enable female employees to experience cultural charm through
Industrial Injury Insurance Maternity Insurance traditional handcrafting, showcase the confident demeanor of women in the
Festival Allowances
Unemployment Insurance Housing Fund new era, and enhance communication among colleagues. The activity consist-
ed of three sessions: “Handmade Flower Hairpin”, “Dried Flower Round Fan
Making” and “Afternoon Tea Talk”. Through immersive handcraft experience
Benefits Health Benefits combined with relaxed interaction, participants stimulated creativity and
System
Annual Physical Examination confidence in creation, narrowed the distance between each other in commu-
Subsidy Benefits nication, and created a warm and harmonious team atmosphere.
Housing Subsidy Seniority Subsidy
Employee Welfare Expenses Meal Subsidy
Holiday Benefits
Academic Qualification Subsidy
Paid Leave Industrial Injury Leave
Overtime Pay / Night Shift Allowance
Sick Leave Maternity Leave, etc.
High-Temperature / Heating Allowance
Occupational Safety Allowance
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 32
Diverse Employee Activities
CASE The Company actively builds diversified leisure spaces, supporting the construction of libraries and gymnasiums. It organizes mini marathons, mindfulness psychological activities
and a year-long healthy weight management program to meet employees’ needs for cultural learning, sports fitness and mental health. The Company plans activities during
Salute to Female Power · Embrace the Beauty of Spring traditional festivals to create a cultural atmosphere and organizes parent-child activities to enhance team cohesion and solidarity.
To celebrate International Women’s Day, the Company’s headquarters
organized a series of themed activities “Enjoy Spring Together, Bloom with
In 2025
Happiness” during the festival. The activity combined floral creation with fun
lucky draws. Female employees made exclusive floral works with abundant
he Labor Union of the Company, together with the Corporate Culture Team, enriched employees’ spare time life and promoted cross-departmental communication by organizing
flower materials and experienced the beauty of spring in creation. A lottery
corporate culture construction activities such as hiking, mountain climbing and camping freely combined by various departments, as well as interest classes in vocal music, dance
draw session was set up on site, with prizes including Apple smart speakers,
and musical instruments and special activities such as the Mid-Autumn Festival Garden Party. In addition, the Company organized sports events such as the “Kangtai Cup” Basket-
cervical spine massagers, vacuum cups and other gifts, and a “universal
ball Match and provided sports facilities including badminton and table tennis, effectively improving employees’ sense of belonging and well-being.
consolation prize” was prepared for all participants. This activity allowed
female employees to effectively release work pressure through floral creation,
created a warm and harmonious corporate atmosphere, and practically
conveyed care and respect for female employees.
Care for Employees in Need
The Company has established a support mechanism for employees in need, providing
special consolation to disadvantaged employees during the Spring Festival. It offers a
one-time subsidy of 5,000 yuan for employees suffering from serious diseases, and
graded one-time hospitalization subsidies ranging from 2,000 to 5,000 yuan for hospi-
talized employees according to their actual conditions. The Company has set up the
Kangxin Fund as an inclusive support fund, through which employees can submit subsi-
dy applications based on their own needs, and the Company will provide support
according to actual situations.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 33
Training and Development Occupational
Health and Safety
Employee Training Key Performance
The Company implements the policy of “Safety First, Prevention Oriented”, strictly abides by the
The Company has formulated the Training and Development System and an annual Work Safety Law of the People’s Republic of China, Law of the People’s Republic of China on the
training plan, and established and improved a talent development platform and During the reporting period, the Company Prevention and Control of Occupational Diseases and other relevant laws and regulations, estab-
training system to continuously enhance employees’ vision and professional compe- lishes a sound occupational health and safety management system, and is committed to creating
tence. Meanwhile, the Company encourages employees to conduct self-develop- a healthy and safe working environment for employees.
ment, continuing education and self-improvement through self-taught examina- Average duration of employee training
tions, online education, professional qualification examinations, professional title
examinations and various training courses held by the society. If employees obtain 12 hours
Indicator Management Objective 2025 Performance
academic certificates, professional and technical qualification certificates, practice
certificates or other credentials relevant to their positions, the Company will provide
various types of support measures according to their specific positions and
Number of Serious
Injuries and Above 0 0
completed courses.
Career Development Key Performance Number of Fire Incidents 0 0
The Company has formulated the Promotion Management Rules, Functional
Department Promotion Management Rules and R&D Center Promotion Manage- During the reporting period, the Company
ment Rules, and constructed a three-channel career development path consisting of
Work Safety Management
the “Management Track”, “Professional Track” and “Research Track”, with job grades the total number of employees receiving regular
divided into ten levels to provide diversified growth opportunities for employees. performance and career development assess-
Meanwhile, the Company has set up a promotion evaluation team and adopted a ments
Management System
hierarchical management strategy combining examination, evaluation and appoint-
The Company has formulated internal work safety system requirements including the Industrial
ment to promote employees’ career development in a fair and impartial manner. % Safety Management Procedures, EHS System Guidelines, Objectives, Indicators and Management
Plans and EHS Post Responsibility System, clarifying that the enterprise principal is the primary
person responsible for work safety. It strictly implements the work safety responsibility system, and
organizes all employees to sign responsibility letters every year to ensure that each employee
clearly understands their respective work safety duties. Meanwhile, the Company actively promotes
the construction of safety culture, and carries out safety education and training through activities
such as safety knowledge competitions and safety consultation days to continuously improve
employees’ awareness of work safety.
As of the end of the reporting period, the Company passed the annual supervision audit of the ISO
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 34
Work Safety Risk Management
The Company has formulated the Hazard Identification and Risk Assessment Management Procedures and Industrial Safety Management Procedures, established a hazard identification
and risk assessment team to identify, evaluate and conduct hierarchical management and control of risks. Corresponding risk control measures are formulated at different levels for identified
hazards of various levels. Meanwhile, the Company has established a normalized potential safety hazard investigation and management mechanism in accordance with the EHS Hazard
Investigation and Management System.
The Company implements full-process management of special •Safety Sign Management Introduce the concept of safety
equipment through measures such as equipment declaration warning signs, including safety colors, contrasting colors and
and licensing, information verification and ledger establish- ! four types of sign styles.
ment, training of operators to eliminate unlicensed operation,
Special Equipment Safety Sign •Stipulate the setting requirements for signs and markings,
Management regular inspection, daily maintenance and self-inspection, and Management
such as placement location, lighting conditions, arrangement
abnormal handling.
order, etc.
CASE
Key Performance
Organizing Safety Film Viewing and Reward-Based Safety BioMinhai Won the First Prize in Confined Space Opera-
Knowledge Quiz tion at the First Work Safety Competition
During the reporting period
During the 24th National “Work Safety Month”, to foster a sound atmosphere of In July 2025, the First Work Safety Competition was carefully organized by the
“Everyone Talks About Safety, Everyone Knows How to Respond — Identifying Administrative Committee of Daxing Biological Pharmaceutical Industry Base, BioKangtai
Potential Safety Hazards Around Us”, the Company held the 2025 Safety Film covering four major events: fire emergency response, hazard investigation, confined
Viewing and Reward-Based Safety Knowledge Quiz. The event consisted of two space operation and electrical safety, aiming to comprehensively enhance the work Carried out special and Completion rate of hazard
sessions: group viewing of work safety-themed films and online-offline integrated safety awareness and emergency response capabilities of enterprises in the park. monthly safety inspections rectification
reward-based safety knowledge quizzes, covering core knowledge points includ- BioMinhai responded actively and quickly formed 3 participating teams, which
ing fire safety, emergency response procedures, and work safety laws and regula- devoted themselves to the competition of fire emergency response, hazard investi- %
tions, with both educational and interactive features. This activity injected new gation and confined space operation with full enthusiasm and solid skills. With solid
vitality into the Company’s safety culture construction, laid a solid foundation for safety knowledge, proficient operational skills and excellent teamwork, BioMinhai
work safety, and promoted the continuous advancement of safety culture to won the first prize in the fiercely competitive confined space operation event, fully BioMinhai
support the sustainable and healthy development of the Company. demonstrating its outstanding management level in work safety, especially in
high-risk operation links, and the strong practical capabilities of its employees. Completion rate of EHS Completion rate of hazard
inspection plan rectification
Carry out special safety
inspections
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 35
Emergency Plans and Drills
The Company has formulated the Control Procedures for Work Safety Emergency Preparedness and Response, and compiled corresponding comprehensive plans, special plans and on-site disposal plans according to the severity of production accidents. It conducts two comprehensive
plan drills and one special plan drill every year, and each department carries out one on-site disposal plan drill annually to improve employees’ emergency response and self-rescue and mutual-rescue capabilities, effectively reducing accident losses and casualties when accidents occur.
Key Performance
During the reporting period
BioKangtai BioMinhai
work safety emergency drills emergency drill plans
fire emergency hazardous chemical confined space sessions
electric shock
drills drill emergency drill accident drill
participants
elevator rescue
drill
food poisoning
emergency drill
summer
heatstroke drill
On-site photo of the Company’s fire drill
Occupational Health Management
The EHS Committee of the Company is responsible for examining and approving the objectives of occupational health and occupational disease prevention and control and the plans for achieving such objectives, and regularly
supervises and inspects the implementation of the plans. It has formulated the Occupational Health Management Procedure, the Labor Protective Equipment Management System and other systems to standardize occupational
health and safety management. Meanwhile, the Company regularly conducts publicity, education and training on the prevention and control of occupational disease hazards, and continuously invests resources to improve
employees’ working conditions, especially the physical environment and supporting facilities of front-line positions such as production, quality inspection and warehousing. The Company firmly believes that sound working
conditions can not only reduce occupational health risks but also enhance employees’ sense of belonging and production efficiency.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 36
Rural Revitalization and Social Public Welfare
BioKangtai has formulated and strictly implemented the External Donation Management System. Since 2022, it has accumulated donations of funds and
materials exceeding 100 million yuan to all sectors of society, benefiting multiple entities including poverty-stricken areas, Red Cross societies, scientific
research institutions and universities. The Company has contributed to supporting the development of medical services, the improvement of public health
services, scientific research and innovation in disease prevention, and the advancement of rural revitalization. It also encourages Party members to partic-
ipate in voluntary services, community co-construction, caring assistance and other activities to repay the society with practical actions. The Company
has won many honors such as “Caring Enterprise”, “Outstanding Contribution Award” and Shenzhen “Glory Cause Contribution Award”, establishing an
image of a responsible corporate citizen.
Health and Medical Accessibility
Expanding Product Coverage Improving Enhancing Public Health Capacity
The Company considers accessibility in product design Product Affordability The Company actively builds a “four-in-one” public health science popularization system integrating online platforms, media
and develops freeze-dried preparations to improve publicity, offline venues and academic conferences, committed to improving national vaccine literacy. Through official accounts
Adhering to the tenet of “Creating Better Vaccines,
adaptability in extreme climate regions. Relying on the such as “Vaccine Science Classroom” and themed publicity on important nodes including World Pneumonia Day, the Company
Benefiting Human Health”, the Company formulates
nationwide distribution of storage agents and a strictly continuously releases authoritative knowledge. It has cooperated with the Chinese Preventive Medicine Association to establish a
scientific and reasonable vaccine prices on the basis
regulated third-party cold-chain distribution network, “Vaccine Science Popularization Base” open to the public and professionals. In addition, the Company disseminates cutting-edge
of full consideration of production costs and market
the Company ensures the safe and timely delivery of science by supporting academic conferences at all levels, and regards science popularization as a long-term strategic work, serving
conditions, striving to provide products with more
vaccines to regions including remote areas. as a useful supplement to government health promotion and consolidating the cornerstone of public immune cognition from
reasonable prices for the public so that people can
multiple dimensions.
While deeply cultivating the domestic market, the obtain safe, effective and high-quality vaccines at
Company actively broadens its international vision, affordable costs. In product R&D, the Company also
arranges overseas business and promotes human health considers adapting to different income groups
and well-being. It has reached cooperation agreements through different dosage forms (vial / pre-filled).
with partners in Indonesia, Pakistan, Bangladesh, Egypt, Meanwhile, the Company has carried out a number of
Turkey and other countries on the overseas registration, activities through channels such as public welfare
promotion, commercial sales, technology transfer and foundations, including donating vaccines, antigen Guangming Pavilion Nanshan Pavilion
other aspects of products including 13-valent Pneumo- (opened in 2020) (opened in 2024)
detection reagents and other supplies to district and
coccal Polysaccharide Conjugate Vaccine, 23-valent Wonderful Moments
county centers for disease control and prevention as
Pneumococcal Polysaccharide Vaccine, Live Attenuated of Vaccine Science
well as Red Cross societies for disease screening and
Varicella Vaccine, and Acellular DTaP-Hib Combined Popularization Visits
vaccination of relevant personnel, and funding health
Vaccine (Quadrivalent Vaccine), joining hands to build a (Partial)
science popularization and disease screening
health barrier. programs.
Daxing Pavilion (opened in 2024)
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 37
Excellence in
Innovation for
Shaping the
Future
of the Industry
Key ESG Topics in this Chapter
R&D and Innovation
Product Quality and Safety
Customer Relationship Management
SDGs Addressed
Supply Chain Management
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 38
R&D and Innovation
Governance
BioKangtai boasts leading R&D and innovation capabilities and is one of the enterprises with the most comprehensive coverage of R&D technology platforms in the vaccine industry. It possesses R&D and production capabilities for viral vaccines, bacterial vaccines,
“
genetically engineered vaccines, conjugate vaccines, combined vaccines and other products, as well as product development capabilities for platform technologies including viral vectors, novel adjuvants and mRNA vaccines. The Company has established a
product development and management architecture responsible for the demonstration and approval of research projects. The Executive Meeting approves R&D project initiation, project implementation plans, registration application materials and other work. It
has formulated systems such as the R&D Center R&D Project Management Procedures to standardize the standardized management of R&D projects.
Live Attenuated Shenzhen Kangtai Biological Products Co., Ltd.
Viral Vaccine Platform Technology Center (National Enterprise Technology Center)
Viral Vector Vaccine 1 Inactivated Viral National & Local Joint Engineering 1
Platform Vaccine Platform Laboratory for Novel Vaccine Development
Beijing Key Laboratory of Synthetic
Intelligent Manufacturing
Shenzhen Engineering
Laboratory for 10
Novel Vaccines
Combined Vaccine Beijing Engineering
Genetically Engineered
Platform
Nine Diversified Vaccines
Guangdong Engineering Mature R&D Vectors
R&D Platforms Laboratory for Therapeutic
Hepatitis B Vaccines
Academician and
Bacterial Polysaccharide Novel Vaccine Adjuvant Expert Workstation Postdoctoral Research Station
Conjugate Vaccine Platform Technology Platform
mRNA Vaccine Bacterial Polysaccharide Beijing Engineering Research Center Beijing International Science and Technology
Platform Vaccine Platform for Novel Combined Vaccines Cooperation Base for Novel Vaccines
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 39
Strategy
The Company owns an internationally advanced vaccine R&D center and always upholds the philosophy of R&D technology engineering and continuous innovation. It has built a multi-level R&D system featuring “independent development as the
core, cooperative development as the support, and technology introduction as supplements”. The Company has successively introduced a number of internationally leading vaccine production technologies from overseas, including Freeze-dried
Human Rabies Vaccine (Human Diploid Cell), Sabin Strain Inactivated Poliomyelitis Vaccine (Vero Cells), etc., laying a solid foundation for the construction of its product pipeline.
Impact, Risk and Opportunity Management Intellectual Property Protection
The Company has formulated the R&D Center R&D Project Management Procedures to standardize the standardized management The Company strictly abides by the Trademark Law of the People’s Republic of China, the Patent Law of the People’s Republic of China
process of R&D projects and improve the transformation capacity of scientific research achievements. and other laws and regulations, and has formulated systems including the Intellectual Property Management Measures and the Patent
Management Measures to strengthen intellectual property management, clarify relevant management responsibilities, encourage inven-
Link Measures tions and creations, enhance the Company’s market competitiveness and promote its sustainable development. During the reporting
period, the Company did not incur any incidents involving infringement of others’ intellectual property rights, nor did it have any intellec-
tual property-related litigation cases.
• In accordance with the Company’s development strategy and market demand for products,
Project Initiation While protecting its own intellectual property rights, the Company fully respects the intellectual property rights of others. In the product
BioKangtai selects topics for proposed R&D projects, prepares project feasibility analysis
development process, intellectual property management personnel participate deeply in all aspects, covering key links such as patented
Review and reports and submits project initiation applications. It conducts technical, economic and legal
technology research, patent infringement analysis and formulation of design-around solutions. It formulates patent layout plans tailored
risk demonstrations for proposed projects, issues evaluation reports after demonstration,
Decision-Making to different types of products. Throughout the R&D process, it closely monitors the output dynamics of innovative achievements and
and formally initiates projects upon approval.
timely evaluates their patentability. Based on an accurate grasp of the rules of various intellectual property application systems, it fully
utilizes these rules to strive for the optimal patent portfolio, thereby enhancing the commercial value of R&D products.
• The project leader exercises control and management over the progress, quality and other
Number of New Patent
aspects of the project, and the implementation is carried out in strict accordance with the 8
Applications in the Year
relevant policies of the National Medical Products Administration and the National Health
Implementation Number of Software
Commission.
Copyrights Held
and Control
• The Scientific Research Management Department organizes the Advisory Committee, Number of Trademarks and
Registration Department and other relevant members to conduct regular evaluations on Character Registrations Held
whether to continue projects based on market conditions, clinical value and other factors.
Number of Copyrights Held 2
Number of Valid Patents Held 100
• Upon achieving phased results, project directors submit applications for phased project
Acceptance acceptance for work in each stage, and the Director of the R&D Center uniformly organizes 0 20 40 60 80 100 120
and completes acceptance for each stage.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 40
Scientific and Technological Ethics Collaborative Innovation
The Company strictly follows R&D ethics in scientific research and innovation, Focusing on cutting-edge technology R&D and industrialization transforma-
and abides by the Declaration of Helsinki and relevant ethical guidelines in tion paths in the vaccine field, the Company actively strengthens innovative
clinical trials. It has established an Animal Ethics Committee and implements cooperation with domestic and foreign research institutes, universities and
the 3R Principles (Reduction, Replacement, Refinement) in animal experiments, high-quality enterprises in the industry, and establishes a long-term and
and builds a graded biosafety protection system to prevent the leakage of stable strategic collaboration mechanism. Through such cooperation models,
biological aerosols and pathogens. the Company continuously attracts top talents and core technical resources in
the industry, effectively promotes joint development in new vaccine technolo-
gies, and provides all-round support for the R&D process and industrializa-
tion of innovative products.
Indicators and Targets
While laying out the development of multi-component and multi-valent vaccines, novel vaccines and upgraded existing vaccines, the Company focuses on applied
research of new vaccine technology paths and the establishment of new technology platforms, including mRNA technology, viral vector technology, novel adjuvant
technology, etc., aiming to meet the escalating public health needs.
Case
A New Milestone in Multi-Component Vaccine Layout – the Fastest-Progressing Domestic Pentavalent Vaccine Launches Phase III Clinical Trials
During the reporting period, the Adsorbed Acellular DTaP-Inactivated Poliomyelitis and Haemophilus influenzae Type b Combined Vaccine (Pentavalent Vaccine) developed
by BioMinhai, a wholly-owned subsidiary of the Company, has officially launched Phase III clinical trials, and successfully enrolled the first subject. The Pentavalent Vaccine is
used to prevent invasive infections caused by diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b. It has advantages such as reducing the number
of vaccinations for infants and young children and improving vaccination compliance among parents and infants. Currently, no domestic product of this kind has been
marketed.
The Pentavalent Vaccine developed by BioMinhai is the first domestic Pentavalent Vaccine to enter Phase III clinical trials and also the fastest-progressing domestic Pentava-
lent Vaccine. If successfully developed, it will break the monopoly of imported products, lay a solid foundation for the R&D of hexavalent vaccines and other multi-component
vaccines, and make greater contributions to the global public health cause.
Unit 2025 Performance
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 41
Product Quality and Safety
Governance Impact, Risk and Opportunity Management
BioKangtai strictly abides by the Pharmaceutical Administration Law of the People’s The Company has established the Quality Risk Management Procedures, which assess, control, communicate and review quality risks throughout the entire product life cycle based on
Republic of China, the Vaccine Administration Law of the People’s Republic of China, the scientific knowledge and objective data to ensure product quality and protect patient health. It controls the outcomes of various uncertainties within the expected acceptable range to
Measures for the Administration of Drug Registration, the Measures for the Administra- ensure that product quality meets requirements. With sufficient knowledge, facts and data, it proactively infers possible future events and avoids hazards through risk control.
tion of Batch Issuance of Biological Products and other laws and regulations. Based on
the ICH Q10 Pharmaceutical Quality System (PQS) theoretical model and in accordance
with regulations such as Good Manufacturing Practice (GMP) for Drugs, the Company Link Measures
has established a quality system covering the entire product life cycle, including drug
R&D, technology transfer, commercial production and product withdrawal. The Company
Identify potential hazard events or possible hazards; conduct qualitative or quantitative analysis on identified risks and evaluate risk levels to
has formulated the Quality Manual, clarifying that the enterprise principal (the Chairman Risk Assessment
support risk prevention and control.
or the General Manager/Executive Deputy General Manager designated by the Chair-
man) is the primary person responsible for drug quality and takes overall charge of the
Company’s daily management.
In accordance with risk assessment results and pre-established risk acceptance principles, when the risk assessment result exceeds the acceptable
Meanwhile, the Company has obtained ISO 9001 quality management system certifica- Risk Control
level, measures shall be taken to reduce or avoid risks.
tion and undergoes GMP inspections by national/provincial/municipal drug regulatory
authorities every year. All inspections in 2025 concluded with a pass.
At each stage of the implementation of risk management procedures, the QA department and relevant departments (drug regulatory system,
Risk Communication industry, patients, internal departments of the Company, etc.) shall exchange and share information on the progress and management, i.e., conduct
Strategy risk communication.
The Company continuously strengthens product quality control, always regards product
quality as the lifeline of the enterprise, deeply practices the quality culture philosophy,
Output of Quality After completing the risk assessment report, the Company follows up on the risk response measures involved to confirm that they are implemented
and has established a comprehensive quality management system covering the entire Risk Management as required and achieve the expected results.
product life cycle including R&D, technology transfer, commercial production, post-mar-
keting management, product sales and after-sales service. It strictly abides by product
quality standards to ensure that all processes such as R&D, production and distribution
Conduct risk supervision and review. If the residual risk is still unacceptable after the implementation of risk response measures, adjust or formulate
comply with relevant laws and regulations. Risk Review
new response measures and evaluate their effects until the residual risk is acceptable.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 42
Product Life Cycle Management Whole-Process Intelligent Digital Management
On the basis of complying with China’s vaccine regulatory system, the Company has fully drawn on and adopted international regulatory guidelines including WHO, ICH, PIC/S and EU_GMP, By introducing advanced information management systems, the Company has
and established a product life cycle pharmaceutical quality management system covering R&D, technology transfer, commercial production and post-marketing management. Strict realized the efficient integration of intelligent digital quality control and compliance
management processes and requirements are set for raw material control, production, vaccine storage and transportation, vaccine application and other links. in all links, promoting the transformation of quality management from the traditional
model to intelligent digital upgrading, and building a solid technical defense for
In addition, the Company has established a closed-loop system covering the entire process from product inspection, non-conforming product handling, problem solving to product recall.
quality and safety. Relying on the intelligent digital architecture information manage-
It not only realizes end-to-end risk management from prevention and control to correction, but also ensures that every link is traceable and improvable.
ment platform, the Company implements the management philosophy of compli-
ance, efficiency and precision into every link of the product life cycle, promotes the
Aspect Measures full integration of quality management services, and ensures the accurate implemen-
tation and efficient execution of quality control measures.
Formulate inspection procedures and Sampling and Retention Management Procedures, Investigation Procedures for Out-of-Limit Laboratory
Product Inspection
Test Results and other documents, and carry out quality inspection and laboratory management in accordance with requirements. Stage Content
Adopt digital tools to integrate and analyze R&D data,
Non-Conforming Implement closed-loop management of non-conforming products from identification, isolation, review to disposal in accordance with the
strictly follow scientific norms and quality standards, and
Product Control Non-Conforming Product Management Procedures. Product R&D
guarantee the reliability and technological innovation of
R&D results.
Formulate the Product Recall Management Procedures with specific provisions on the scope, responsibilities and contents of finished product
Product Recall
recall, ensuring that finished product recall can be initiated at any time and organized quickly and effectively. Establish a dynamic evaluation model and access mecha-
nism through the supplier management information
system, realizing full-chain digital process management
Raw Material
from supplier qualification review, raw material quality
Procurement
evaluation to raw material access, and advancing quality
The Company classifies product recalls into voluntary recalls and mandatory recalls according to recall circumstances, and divides them into Class I, Class II and Class III recalls based on
management to the source of the raw material supply
the severity of pharmaceutical quality defects or other potential safety hazards. Regular simulated recalls are conducted to evaluate and ensure the effectiveness of the product recall chain.
system. During the reporting period, no product withdrawal or recall incident due to health and safety reasons occurred in the Company. The Company has formulated Finished Product
Recall Procedures, which stipulate the applicable scope, responsibilities and specific contents of recalls to ensure that recall operations can be initiated at any time and implemented
promptly and effectively. The recall process is as follows: after a quality incident occurs, report to the Pharmaceutical Safety Committee, initiate pharmaceutical safety risk investigation and Take the Manufacturing Execution System (MES) as the
assessment, and decide whether to launch a recall; implement the recall, formulate and implement corrective and preventive actions, and track implementation effectiveness; close the core to implement online monitoring of the entire produc-
Manufacturing tion line, collect and monitor process parameters in real
recall action upon meeting requirements, and archive records of the entire process.
Process time, ensure process robustness between batches and
consistency and stability of product quality, and realize
transparency and controllability of the production process.
Integrate advanced testing instruments and Laboratory
Information Management System (LIMS) into an intelligent
Product Inspection digital inspection and analysis platform, ensuring the
and Release accuracy and traceability of product inspection data, so
that every batch of released products meets quality
standards.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 43
Quality Culture Construction Indicators and Targets
Case Indicator 2025 Performance
Organizing Data Integrity Training to Consolidate the Compliance Bottom Line
Data integrity is the bottom-line requirement of regulatory compliance and also the cornerstone of vaccine safety. In 2025, the Company organized three series of data
integrity-themed training sessions covering more than 700 people in total, namely “Strengthening Quality Awareness, Consolidating the Vaccine Safety Line”, “Principle
Number of Product Recalls 0 Case
Analysis of Data Integrity Risks and Governance” and “Sharing of Data Integrity Risks in Quality Inspections”, aiming to strengthen quality awareness and consolidate the
vaccine safety line. Number of Product Quality
Training Sessions 7,434 Session
Number of Enterprises
with Quality Management
System Certification 5 Enterprise
Improvement of Product Quality
he Company attaches great importance to product quality and safety, and organizes training courses including management procedures for corrective and preventive actions and personnel hygiene management procedures. The Company formulates an annual GMP self-inspec-
tion plan and regularly conducts GMP self-inspections, combined with routine quality inspections, to monitor the operation of the Company's quality management system, assess compliance with GMP and other relevant regulatory requirements, and propose necessary correc-
tive and preventive actions. In addition, the Company accepts irregular audits from external authorities such as the National Medical Products Administration and the Guangdong Medical Products Administration. On the basis of complying with China's vaccine regulatory system,
the Company has drawn on international guidelines including WHO, ICH, PIC/S and EU GMP to establish a full life cycle pharmaceutical quality management system covering product research and development, technology transfer, commercial production and post-marketing
management. Strict management procedures have been established for raw material control, product production, vaccine storage, transportation and application. The Company has formulated systems such as Material Management Procedures and Supplier Management
Procedures, and implements full-process access control over material procurement, acceptance, inspection, storage, release and use against material lists and quality standards. Meanwhile, it has developed production procedures and operational procedures for each product
to guide production operations and quality monitoring, and continuously conducts product quality monitoring and stability studies to ensure the stable production of products meeting intended uses and registration requirements. In view of the strict storage and transportation
conditions for vaccines, the Company conducts periodic verification of cold chain facilities and vehicles, and adopts an advanced online monitoring system to realize full-process cold chain temperature monitoring, ensuring the safety and reliability of storage and transportation.
Protecting patient health is the mission and responsibility of vaccine practitioners. To this end, the Company has established smooth customer feedback channels and handling mechanisms, set up a dedicated pharmacovigilance department, and conducts signal detection,
evaluation and management of AEFI information.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 44
Customer Relationship Management
The Company adheres to the development strategy of “bringing in advanced technologies and going global with domestic vaccines”, and maintains friendly
and win-win relations with partners through finished product distribution, bulk export, technology transfer and other approaches. It focuses on introducing
“ Responsible Marketing
internationally advanced technologies to enrich its own technology layout and reserves, and enhances independent innovation capability on the basis of
introduction and absorption, so as to promote the transformation of independent innovative technological achievements. In addition, while deeply cultivating The Company strictly abides by the Advertisement Law of the People’s
the domestic market and continuously optimizing the sales network layout, the Company keeps increasing the expansion of international business and Republic of China, the Trademark Law of the People’s Republic of China
promotes its products to the global market. At present, overseas business covers Southeast Asia, South Asia, the Middle East, Africa, Latin America and other and other laws and regulations, and upholds the principles of accuracy,
regions, with products including 13-valent and 23-valent pneumococcal vaccines, varicella vaccine, combined vaccines and other varieties. clarity and transparency in market promotion. False advertising is strictly
prohibited in the marketing process. The Company has formulated the
Customer Complaint Handling
The Company has established sound customer communication channels and complaint management processes, and timely collects customer feedback through multiple channels
such as the 400 service hotline and customer feedback collection to ensure unimpeded communication. It has formulated the User Complaint Management Procedures, which speci-
fy the handling processes for medical inquiries and quality complaints respectively. Upon receiving inquiries, the Company replies with information in accordance with the Operating
Procedures for Medical Inquiry and Complaint Handling. Upon receiving quality complaints, it promptly conducts internal communication and investigation in accordance with the
Customer Feedback and Complaint Management Procedures, and organizes relevant departments to formulate corrective and preventive measures to ensure timely and proper
“
Management System for the Production, Collection and Use of Promotion-
al Materials and Products, which clarifies the production process and
approval procedures for promotional materials and regulates the compli-
ance review of market promotion materials. Product promotional materials
are compiled by the product team, reviewed by the Medical Affairs Depart-
ment, verified by the Marketing and Medical Directors, and finally
approved by the Marketing Center head to ensure the accuracy, clarity and
transparency of market promotion materials.
resolution of issues.
Custommer Ouality Commplaint Process Key Perforimance Indicators:
The Marketing Center collects customer feedback and receives During the reporting period, the Company
Improve customer
satisfaction
customer complaint information.
Achieved a
The Company conducts customer satisfaction surveys in a timely manner
customer complaint resolution rate.
to fully understand customer opinions and suggestions, and continuously
The Quality Assurance Department organizes relevant
improves service quality guided by customer needs. The Company attach-
departments to conduct investigations and forimuilate
es great importance to customer feedback, continuously optimizes proce-
corrective and preventive actions.
dures for the investigation, handling, tracking and supervision of customer
complaints, conducts retrospective analysis of customer feedback and
makes active improvements to systematically enhance customer satisfac-
tion.
The Marketing Center assists in the investigation, responds
to customers, and closes the complaint.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 45
Supply Chain Management
Governance
In accordance with the Good Manufacturing Practice (GMP) for Drugs and other laws and regulations, the Company has formulated systems including the Supplier Management Measures
“
and Procurement Management System to continuously standardize procurement processes and optimize supplier management. It applies a digital procurement system to reduce error rates
from contract approval to material warehousing and improve work efficiency.
• Strictly control supplier access qualifications, set
general qualification requirements and category-spe-
cific qualification requirements by supplier category,
• Establish a supplier review and evaluation team to and material quality standards to ensure compliance
assess suppliers using quantified scoring criteria, cover- Supplier Access with quality and technical standards for production.
ing quality control, delivery timeliness, cost manage-
ment, service level and other aspects.
• Assessors shall fill in the Supplier Assessment Form
during evaluation and take corresponding actions based Supplier Assessment
on the results. and Evaluation
• After evaluation, purchasers shall promptly notify
suppliers of the evaluation criteria and results in writing,
take corresponding measures and put forward sugges-
tions according to the evaluation outcomes. 3
Supplier Information • Upon receiving a notice of supplier information
Change change, purchasers shall identify and confirm wheth-
services. Changes to suppliers of production materi-
• Suppliers failing to meet standards shall be eliminated in a
als shall also comply with the GMP change control
timely manner.
Supplier management documents.
• Elimination of suppliers of production materials shall be Elimination
carried out in strict accordance with the Company’s GMP
supplier management procedures.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 46
Strategy Indicators and Targets
The Company is committed to building a supply chain system featuring resilience, transparency and responsibility. Through stringent access thresholds, digital traceability
systems and strategic reserve mechanisms, it ensures the stable supply and quality safety of key materials. Meanwhile, the Company actively practices responsible procurement,
integrates environmental performance and business ethics into the whole life cycle management of suppliers, and promotes the sustainable development of the biopharmaceu- Indicator Unit 2025 Performance
tical industrial chain.
Impact, Risk and Opportunity Management Total Number of Suppliers Unit
Resilience Management Sustainable Supply Chain Development
Percentage of Suppliers
%
Signing the Supplier Code of Conduct
BioKangtai systematically constructs a supply chain resilience management system The Company adheres to the principles of integrity-based cooperation and mutual
through diversified layout and full-process control. The Company continuously benefit, and is committed to building a compliant, integrity-based and sustainable
promotes the domestic substitution of key imported materials, implements a supply chain system with partners to protect the legitimate rights and interests of
multi-supplier strategy for core materials, and combines dynamic safety stocks to suppliers. It has formulated and implemented the Supplier Code of Conduct, which Percentage of Suppliers Signing
effectively insulate against supply disruption risks. On the quality control front, full
inspection is conducted for all materials upon arrival, and transportation specifica-
puts forward clear requirements for suppliers’ behavior from multiple dimensions
including legal compliance, human rights and labor, environmental protection, and
Contracts with Environmental
and Labor Requirements Clauses
%
tions are clearly defined through contracts and quality agreements. Relying on the business ethics to ensure a transparent and regulated supply chain during the
Warehouse Management System (WMS), a unique traceability code is assigned to operation.
materials upon warehousing, realizing full-process information traceability from
Meanwhile, the Company deeply integrates the two dimensions of green logistics
warehousing to distribution.
and biosafety to comprehensively reduce environmental footprint and strengthen
risk control. In the logistics link, the Company optimizes routes through the "trunk
Equal Treatment of Small and Medium-sized line + regional" hybrid distribution model, plans the shortest path using intelligent
Enterprises software, and sets distance and network constraints on third-party carriers to
effectively reduce energy consumption. In terms of special material control,
full-process closed management is strictly implemented for customs-supervised
Upholding the principles of fairness, impartiality and mutual benefit, the Company materials such as imported virus strains, which are managed exclusively by desig-
treats small and medium-sized enterprises (SMEs) equally, standardizes contract nated personnel in P2 (BSL-2) laboratories after risk assessment and approval, and
performance and payment procedures, and effectively safeguards the legitimate are subject to customs inspection throughout the process.
rights and interests of SMEs. It also firmly eliminates unreasonable payment terms
and invisible thresholds, fostering a fair and transparent cooperative environment.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 47
Collaboration with Case
Industry Peers
practical experience and development achievements, and promotes
“
The Company actively participates in various industry activities, shares
the sustainable development of the industry. In the future, the Company
will continue to act as a “leader” in technological innovation for the
biopharmaceutical industry, continuously strengthen the industrial
Executive of BioKangtai and BioMinhai Awarded the “Outstanding Achievement Award of the 19th Pharmacy Development Award”
In November 2025, the award ceremony of the 19th Pharmacy Development Award was held in Beijing. Attendees of the
ceremony included Chen Zhili, former State Councilor and Vice Chairperson of the 11th Standing Committee of the National
People's Congress, Academician Zhang Boli, Academician Chen Kaixian, Academician Zhang Gaiping, Academician Yue
Jianmin, Academician Wang Junzhi, Academician Xia Ningshao, as well as more than 300 experts and scholars from
renowned universities, research institutes, and medical institutions.
The 19th Pharmacy
Development Award for
Outstanding Achievements
Liu Jiankai, Director and Vice President of BioKangtai and Executive Deputy General Manager of BioMinhai, was awarded the “Outstanding Achievement Award”. Follow-
cluster effect, and make greater contributions to promoting the overall ing the award ceremony, a series of academic exchanges were held. Among them, the Vaccine Innovation Forum themed “Focusing on Frontiers, Interdisciplinary Integra-
high-quality development of China's pharmaceutical and health sector. tion, and Translational Application” was co-organized by BioMinhai, a wholly-owned subsidiary of BioKangtai Experts attending this academic event included academi-
cians of the Chinese Academy of Engineering, renowned university scholars, medical experts, and enterprise representatives, who gathered to discuss cutting-edge
topics and industrialization paths of global vaccine research and development.
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 48
Appendices
About this Report
This report is the fifth Environmental, Social, and Governance (ESG) report released by BioKangtai.
Report Scope Data Sources
This Report takes Shenzhen Kangtai Biological Products Co., Ltd. as the main entity and covers its subsidiaries. Unless otherwise Data used in this report include official government statistics, internal statistical statements, third-party questionnaires, administrative
specified, the scope of this Report is consistent with that of the Company’s annual report. documents and reports, third-party evaluations and interviews, etc.
Time Period Reliability Statement
This report is an annual report covering the period from January 1 to December 31, 2025. Certain content may exceed the aforemen- The Company confirms that this report contains no false records, misleading statements or material omissions.
tioned period, and clarification will be provided where applicable.
Definitions
Access to the Report
Term Refers to Full Name This report is available for review and download on the Company’s website (http://www.biokangtai.com) and the Shenzhen Stock
Exchange website (http://www.szse.cn), and the CNINFO website (http://www.cninfo.com.cn). This report is published in both Chinese
and English. The English version is translated from the Chinese version. In the event of any discrepancy between the two versions, the
BioKangtai, the Company, We Refers to Shenzhen Kangtai Biological Products Co., Ltd.
Chinese version shall prevail.
BioMinhai Refers to Beijing Minhai Biotechnology Co., Ltd., a wholly-owned subsidiary
Preparation Basis
• Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 17 – Sustainable Development Report (for Trial
Implementation)
• Shenzhen Stock Exchange Self-Regulatory Guidelines for GEM Listed Companies No. 3 – Preparation of Sustainable Development
Reports
• United Nations Sustainable Development Goals (SDGs)
• Global Reporting Initiative GRI Standards: Sustainable Development Reporting (2021 edition)
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 49
ESG Performance Table
Indicator Unit 2025 Performance Indicator Unit 2025 Performance
Total Number of Directors person 7 Sessions of Anti-Corruption Training session 2
Sessions of Training Organized for Board Members session 4 Number of Valid Patents Held piece 100
Number of Board Meetings Held session 7 Number of Valid Patents Per Hundred Million RMB of Revenue piece/CNY 3.74
Attendance Rate of Board Members % 100 Number of Copyrights Held piece 2
Number of General Meetings of Shareholders Held session 4 Number of Trademarks and Literal Registration Rights Held piece 29
Number of Audit Committee Meetings Held session 4 Number of Software Copyrights Held piece 14
Number of Nomination Committee Meetings Held session 3 Number of Software Copyrights Per Hundred Million RMB of Revenue piece/CNY 0.52
Number of Remuneration and Evaluation Committee Meetings Held session 3 Number of New Patent Applications Filed in the Year piece 8
Number of Strategy Committee Meetings Held session 2 Total Number of Employees person 1,957
Proportion of Independent Directors in the Audit Committee % 66.67 Number of R&D Employees person 353
Proportion of Independent Directors in the Remuneration Committee % 66.67 Number of Labor Dispatch Employees person 20
Proportion of Independent Directors in the Nomination Committee % 66.67 Number of Part-Time Employees person 16
Number of Employees Receiving Compliance Training person 150 Number of Female Employees person 743
Total Hours of Employee Compliance Training hour 4 Proportion of Female Employees % 37.96
Sessions of Compliance Training Organized by the Company session 2 Number of Ethnic Minority Employees person 110
Total Number of Employees Receiving Anti-Corruption Training person 150 Proportion of Ethnic Minority Employees % 5.6
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 50
Indicator Unit 2025 Performance Indicator Unit 2025 Performance
Number of Employee Attrition / Turnover person 167 Total Water Intake from All Regions megaliter 1,287.78102678
Employee Attrition Rate / Turnover Rate % 7.9 Total Volume of Recycled / Reclaimed Water megaliter 82,362
Total Training Hours for Employees hour 6,751 Total Wastewater Discharge Volume cubic meter 1,196,225.064
Average Training Hours Per Employee hour 12
Chemical Oxygen Demand (COD) Note: Statistics from Kangtai Bio. mg/L 0.72251064461348
Percentage of Total Employees Receiving Regular Performance and Career
% 100
Development Appraisals Ammonia Nitrogen Note: Statistics from BioKangtai. mg/L 0.01529074763054
Employee Training Coverage Rate % 100
Total Phosphorus Note: Statistics from BioKangtai. mg/L 0.00845600555195333
Natural Gas cubic meter 9,168.715
Total Volume of Recyclable Waste ton 27
Lique?ed Petroleum Gas ton 0
Total Volume of General Solid Waste ton 116.604
Steam cubic meter 212,587.21
Total Recycled Volume of General Solid Waste Note: Statistics from BioMinhai. ton 48.185
Raw Coal ton 0
Total Volume of Hazardous Waste ton 254.211149
Diesel Oil liter 79,780
Environmental Protection Investment ten thousand RMB 178.2
Gasoline liter 24,190
Total Investment in Energy Conservation and Emission Reduction ten thousand RMB 0
Fuel Oil Note: Consumption of gasoline and diesel by vehicles only covers
ton 0
company-owned vehicles, excluding third-party transportation vehicles.
Total Value of Material Fines Imposed for Violations of Environmental
Renewable Energy? Note: As de?ned in ISO/IEC CD 13273-1.2, ten thousand RMB 0
Laws and / or Regulations
renewable energy includes wind, solar, hydro, geothermal energy, etc. kWh 36,532,400
Total Number of Non-Monetary Sanctions Imposed for Violations of Environmental
case 0
Purchased Electricity Note: If there are overseas operating sites, please Laws and / or Regulations
kWh 95,956,240
separately specify the purchased electricity in such countries or regions.
Number of Occupational Disease Cases person 0
Direct (Scope 1) Greenhouse Gas Emissions metric ton of equivalent 15,000.69
Number of Work-Related Fatal Accidents case 0
Energy-Indirect (Scope 2) Greenhouse Gas Emissions metric ton of equivalent 41,496.81
metric ton of equivalent / Number of Deaths from Work-Related Accidents person 0
Greenhouse Gas Emission Intensity 0.33
operating revenue or sales
Greenhouse Gas Emission Reduction Volume metric ton of equivalent 22,065.57 Fatality Rate Per Million Working Hours % 0
Environmental, Social and Governance (ESG) Report 2025 Part One Integrity Governance Efficient operation Coagulation symbiosis Innovation Excellence appendix 51
Indicator Unit 2025 Performance Dimension No. Topic Corresponding Clause Corresponding Chapter
Percentage of Security Personnel Who Have Received Formal Training on Organizational 3 Waste Management Article 31 Pollutant Emissions and Waste Management
Labor Rights Policies or Speci?c Procedures and Their Application % 100
Note: Statistics from BioKangtai.
Investment in Employee Occupational Health and Safety ten thousand RMB 67.23 5 Environmental Compliance Management Article 33 Environmental Compliance Management
Environment
Work Safety Investment ten thousand RMB 223.18 6 Energy Utilization Article 35 Resource Utilization and Circular Economy
Total Number of Suppliers unit 1,466 7 Water Resource Utilization Article 36 Resource Utilization and Circular Economy
Percentage of Suppliers That Have Signed the Supplier Code of Conduct % 100 8 Circular Economy Article 37 Resource Utilization and Circular Economy
Percentage of Suppliers That Have Signed Contracts Including Clauses
% 100 9 Rural Revitalization Article 39 Rural Revitalization and Social Public Welfare
on Environmental and Labor Requirements
Number of Product Recall Incidents case 0 10 Social Contribution Article 40 Rural Revitalization and Social Public Welfare
Sessions of Product Quality Training session 7,434 11 R&D and Innovation Article 42 R&D and Innovation
Number of Enterprises Certi?ed with Quality Management Systems unit 5 12 Tech Ethics Article 43 R&D and Innovation
Social 13 Supply Chain Security Article 45 Supply Chain Management
ESG Indicator Index 16 Data Security and Customer Privacy Protection Article 48 Information Security Protection
Employee Rights and Interests, Training and
Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock 17 Employees Article 50
Development,Occupational Health and Safety
Exchange No.17 – Sustainable Development Reports (for Trial Implementation)
Sustainable
Dimension No. Topic Corresponding Clause Corresponding Chapter 19 Stakeholder Communication Article 53 Stakeholder Communication
Development-
Related
Governance
Environment
首页
微信公众号
证券之星APP
